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1. INTRODUCTION 
 
Infertility is a growing public health issue, with the male factor accounting for almost 
50% of all cases. Inflammation of the testis and the genital tract represents one of the 
causes of male infertility. Therefore, in the first part of this study, we examined the 
development and characteristics of autoimmune orchitis, a chronic testicular 
inflammation of the testis, in a mouse model. We also determined the expression of 
activin A and B, regulators of spermatogenesis and steroidogenesis under normal 
conditions, during the development of this disease as cytokines involved in inflammation 
and fibrosis. In the second part of this study, we designed a potential therapeutical 
model of testicular inflammation based on our results from the first part of the study. 
 
1.1. The male reproductive tract 
The male reproductive tract comprises the gonads, namely the testes where 
spermatogenesis and steroidogenesis take place, the rete testis and the efferent ducts 
that connect the testis to the epididymis, where the sperm mature and acquire their 
motility and capacity to fertilize the egg, and are stored. Sperm maturation is completed 
under the influence of the secretions of the accessory glands (seminal vesicles, prostate 
and bulbo-urethral glands) during ejaculation, when they are propelled into the vas 
deferens and ejaculated through the urethra (Meniru, 2001). 
 
1.2. The testis: structure and function 
The testes are formed from the sex cords, under regulation by the SRY gene, located 
on the Y chromosome (Koopman et al., 1990). Expression of SRY, and its downstream 
target Sox9, is restricted to somatic cell precursors that give rise to the epithelial Sertoli 
cell lineage (Morais da Silva et al., 1996). This process is critical in testis 
morphogenesis, as it is considered to regulate all subsequent events of testis 
development; namely, establishment of the testis vasculature, testis cord formation and 
differentiation of other male-specific cell lineages, peritubular myoid cells and fetal 
Leydig cells (Brennan and Capel, 2004). Consequently, the Sertoli cells and peritubular 
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myoid cells contribute to the deposition of the basal lamina that leads to the separation 
of the testis into two distinct compartments: (a) the seminiferous epithelium, where 
Sertoli cells and germ cells are sequestrated within the testis cords, and (b) the 
mesenchymal compartment (interstitium), where steroidogenesis occurs in Leydig cells 
synthesizing androgens. Later in fetal development, the testis cords undergo elongation, 
expansion and coiling to form the seminiferous tubules under the influence of activin A 
(Archambeault and Yao, 2010). Moreover, during fetal life activin A promotes Sertoli cell 
proliferation (Archambeault et al., 2011). During pubertal development, Sertoli cells stop 
proliferation (Orth, 1982), align to the basal lamina of the seminiferous tubules and form 
inter-Sertoli tight junctions, gap and adherens junctions, which form the blood-testis-
barrier (BTB) and contribute to establishment of the immune competence of the testis 
(detailed description in section 1.4.) During the process of sperm production, Sertoli 
cells provide numerous structural and functional interactions with the developing germ 
cells. The Sertoli cells form unique branches from their cytoplasm that surround and 
provide physical support for germ cell development, spermiation (the process of sperm 
release) and phagocytosis of the residual germ cell cytoplasm (Lyon et al., 2015). They 
also express transport proteins and growth factors crucial for germ cell development, 
such as transferrin, inhibins, activins and many others. Due to these characteristics, 
Sertoli cells are referred to as “mother cells” or “nursing cells”. 
 
1.2.1. Spermato- and spermiogenesis 
The testis is the site of production of the male gametes, i.e. spermatozoa, through a 
complex biological process known as spermatogenesis. Essential to this process is the 
intimate association between developing germ cells and their somatic nursing cells, the 
Sertoli cells, which provide structural and nutritional support to germ cells at all stages 
of their development. In the adult testis, germ cells at different phases of development 
are constantly interacting with one another (Haverfield et al., 2014). There are three 
main phases of spermatogenesis: mitosis, meiosis and spermiogenesis; illustrated in 
Figure 1. Adjacent to the basal lamina, the pool of spermatogonial stem cells is 
maintained by continual mitosis, whereas the most differentiated spermatogonia enter 
meiosis to produce haploid spermatocytes. These round haploid spermatids undergo a 
 Introduction 
 
- 3 - 
 
complex series of morphological changes (without division) to form elongated 
spermatids. This final phase of spermatogenesis is called spermiogenesis.  
During this process, the acrosome is formed from the Golgi apparatus. The acrosome is 
a membrane-bound lysosome-like structure containing proteins, such as acrosomal 
hydrolases, that enable the sperm to penetrate through the layers surrounding the 
oocyte during fertilization (Yanagimachi, 1994). While the acrosome is formed on one 
side of the nucleus of the round spermatid, the flagellum starts to form on the opposite 
side by pairing of the centrioles. The flagellum, or sperm tail, largely consists of a 
microtubular structure known as the axoneme. The mid-piece of the tail is rich in 
mitochondria that contribute to the motility of the sperm. Towards the end of 
spermiogenesis, the chromatin material becomes condensed in the sperm nucleus and 
most of the spermatid cytoplasm becomes sequestrated and compacted in a residual 
body, remaining attached to the Sertoli cells. Spermatids are then released as individual 
cells, or spermatozoa. The process of release of these spermatozoa into the tubular 
lumen is known as spermiation. Each generation of spermatogonia, spermatocytes and 
spermatids form specific cellular associations with other generations in a cyclic manner 
and these distinct associations are divided into stages, which collectively represent the 
cycle of the seminiferous epithelium. In mice, the cycle of the seminiferous tubules has 
been divided into 12 stages (I-XII) (Oakberg, 1956). Overall, the goal of 
spermatogenesis is to create the structures that facilitate the spermatozoa in reaching 
and fertilizing the oocyte. 
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Figure 1: Spermatogenesis: the process of formation of haploid spermatozoa 
(sperm cells) from undifferentiated diploid spermatogonia. 
This process involves a multiplication phase (mitosis), maturation and differentiation 
phase (meiosis) ending by spermiogenesis which is the transformation of the haploid 
spermatids into spermatozoa.  
(from: http://www.majordifferences.com/2013/06/difference-between-spermatogenesis-
and.html#.V7G8Xfl97IU) 
 
1.2.2. Steroidogenesis and the hypothalamic-pituitary-gonadal axis 
In the male, spermatogenesis is regulated by a complex interaction between circulating 
hormones, i.e. gonadotropins, follicle-stimulating hormone (FSH) and luteinizing 
hormone (LH), and locally produced factors, including activins, inhibins and the sex 
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steroids produced by the testis, namely androgens and estrogens (Mather et al., 1997, 
de Kretser et al., 2001). These hormones and factors comprise the hypothalamic-
pituitary-gonadal (HPG) axis. Both LH and FSH are glycoprotein hormones produced by 
the anterior pituitary after stimulation by the gonadotropin releasing hormone (GnRH), 
which is secreted by the hypothalamus and constitutes the initial step of the HPG axis. 
Steroidogenesis entails processes by which cholesterol is converted to biologically-
active steroid hormones within mitochondria and smooth endoplasmic reticulum (Figure 
2). The most important steroid hormone produced by the testis is testosterone. 
Testosterone is part of the androgen family of hormones and is produced by Leydig 
cells (Zhao et al., 2016). Androgens play a critical role in the development of the male 
phenotype and sexual behavior. Steroidogenesis in Leydig cells is regulated mainly by 
LH, while Sertoli cell function is regulated by FSH and testosterone.  
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Figure 2: Steroidogenesis. 
Steroids are synthesized from cholesterol through a series of enzymatic reactions. StAR 
(steroidogenic acute regulatory protein) regulates cholesterol transfer into the 
mitochondria, where it gets converted to pregnenolone by an enzyme called Cyp11a1 
(Cytochrome P450, family 11, subfamily a, polypeptide 1; side chain cleavage enzyme; 
desmolase). Pregnenolone is the precursor for the synthesis of all steroid hormones 
after it gets metabolized in the smooth endoplasmic reticulum by Cyp17a1 (Cytochrome 
P450, family 17, subfamily a, polypeptide 1) and Hsd3b1 (Hydroxy-delta-5-steroid 
dehydrogenase, 3 beta- and steroid delta-isomerase cluster) enzymes. Steroids are 
divided into five groups of molecules: progestogens, such as progesterone, 
mineralocorticoids, glucocorticoids, androgens, such as testosterone and estrogens 
such as estradiol. Akr1c3: Aldo-keto reductase family 1, member C3; Cyp21a1: 
Cytochrome P450, family 21, subfamily a, polypeptide 1.  
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Secretion of both gonadotropins by the pituitary is regulated by circulating testosterone 
from the testis, and FSH is also regulated by activin, inhibin and follistatin as presented 
in Figure 3. Inhibin from the testis exerts its action at the pituitary to suppress FSH 
secretion, whereas locally-produced activin stimulates FSH secretion, as discussed in 
section 1.5. 
 
Figure 3: The hypothalamic-pituitary-testis axis and its hormonal regulation. 
Testosterone, activin, inhibin and follistatin are produced by the testis and/or the 
pituitary. Gonadotropins are secreted by the pituitary after GnRH and activin stimulation, 
whereas inhibin and follistatin inhibit their secretion. Testosterone regulates its own 
secretion through negative feedback at the hypothalamus and the pituitary. GnRH: 
gonadotropin releasing hormone, FSH: follicle stimulating hormone, LH: luteinizing 
hormone. 
 
1.3. The immune system 
The immune system is the collection of cells, tissues and molecules that protect the 
body from pathogens. The cells of the immune system are called leukocytes and are 
produced in the bone marrow by a process called hematopoiesis. They circulate in the 
blood and lymph and their role is profoundly influenced by the tissue in which they are 
located at any particular time (Janeway, 2001). The protection against pathogens by the 
immune system can be divided into innate and adaptive immune responses (also called 
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antigen-specific immune response). A simplified scheme of the innate and adaptive 
immune responses is shown in Figure 4. 
 
Figure 4: Simplified schematic representation of the innate and adaptive immune 
responses. 
Effectors of innate immunity (neutrophils and macrophages) are activated after invasion 
of a foreign organism, such as bacteria or fungi, through biological barriers and surfaces 
of the body. They start secreting cytokines and contribute to the maturation of dendritic 
cells. Mature dendritic cells constitute the first step of adaptive immunity as they present 
the foreign antigens to T cells. In turn, differentiated T cells (TH1, TH2, Treg) become 
activated and secrete specific cytokines (tumor necrosis factor [TNF], interferon- [IFN-
, interleukin-4 [IL-4], IL-5, IL-10 and IL-12) and activated B cells secrete antigen-
specific antibodies and cytokines (IL-10, IL-12 and IL-18) (from (Romani, 2004). 
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In brief, the innate immune response is the first line of defense against many common 
microorganisms. Circulating monocytes rapidly differentiate into macrophages once 
they are out of circulation, and enter tissues. Once the pathogen enters the tissues, 
usually through an epithelial barrier, it gets recognized by Toll-like receptors (TLRs) or 
other pattern recognition receptors present on the immune cells through its pathogen-
associated molecular patterns, or PAMPs, which are small molecule patterns conserved 
within a class of pathogens. For example, bacterial lipopolysaccharides (LPS) found on 
the cell membranes of bacteria are PAMPS that get recognized by TLR4 of immune 
cells of the innate immune system. The pathogen then gets phagocytosed by tissue 
resident macrophages that start secreting cytokines and chemokines in order to attract 
neutrophils and monocytes from the bloodstream. The cytokines and chemokines 
released by macrophages in response to bacterial constituents initiate the process 
known as inflammation. In this regard, it is important to mention here the macrophage 
dichotomy, which means that macrophages are divided into two different phenotypes 
depending on their stimuli. More specifically, tissue resident macrophages generally 
have an M2 anti-inflammatory phenotype, while activated macrophages possess an M1 
pro-inflammatory phenotype (Martinez and Gordon, 2014). Accumulation of neutrophils 
and mast cells in a tissue is also a sign of inflammation. Neutrophils, together with the 
activated macrophages, provide rapid and effective phagocytosis of microorganisms 
and cell debris, while mast cells promote the development of the inflammatory response 
through secretion of leukotactic agents, and promote fibrosis and scarring through 
degranulation and secretion of tryptase (Wilgus and Wulff, 2014). The innate immune 
response subsequently contributes to activation of the adaptive immune response. More 
precisely, tissue-residing immature dendritic cells phagocytose pathogen antigens in the 
infected tissue, get activated and undergo maturation into antigen-presenting cells 
(APC) that migrate to the nearest lymph node and present the pathogenic antigen via 
the major histocompatibility complex (MHC) to naïve T lymphocytes, which are the main 
regulators of adaptive immunity. T cells recognize the antigen bound to the MHC 
through their T-cell receptor (TCR). This leads to recruitment, activation and 
proliferation of the antigen-specific lymphocytes, both T cells and B cells, which mediate 
adaptive immunity. B cells are activated by antigen-specific T cells and exposure to 
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soluble antigen, and start secreting antibodies directed against the antigen, while 
different T cell subtypes are activated after recognition of their antigen presented on 
MHC class I or II molecules. Namely, CD8+ cytotoxic T cells recognize antigens on the 
MHC class I present on somatic cells, and therefore play an important role in protection 
against viral infections and transformed tumorigenic cells, while CD4+ “helper” T cells 
recognize antigens on the MHC class II existing on APC, as shown in Figure 5 (Hedger, 
1997). 
 
Figure 5: Simplified schematic representation of the activation of leukocytes 
during the immune response. 
The immune response begins with presentation of an antigen, attached to a major 
histocompatibility complex (MHC) molecule, to an antigen-specific T lymphocyte (T cell). 
Most somatic cells (C) express MHC class I antigens on their surface, and can present 
antigens to CD8+ cytotoxic T cells (Tc cells). Antigen-presenting cells (APC), which 
express MHC class II molecules on their surface (for example, dendritic cells and 
activated macrophages) present antigens to CD4+ ‘helper’ T cells (TH cells). At the 
same time, antigen-specific B lymphocytes (B cells) will be primed by exposure to 
soluble antigen via their surface immunoglobulin receptors. Infiltrating mast cells (M) 
and polymorphonuclear cells (P) contribute to the inflammation. (From (Hedger, 1997). 
 
Tolerance towards self-antigens prevents development of autoimmune diseases. It is 
achieved by both central and peripheral tolerance. On one hand, central tolerance is 
carried out when thymocytes that have a TCR with low affinity for self-peptide-MHC 
complexes are positively selected to further differentiate and function in adaptive 
immunity, while autoreactive T cell clones are deleted in the thymus. On the other hand, 
peripheral tolerance is accomplished by the suppressive influence of 
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CD4+CD25+FoxP3+ regulatory T cells (Tregs) against specific antigens in the periphery 
(Burt, 2013, Xing and Hogquist, 2012). 
Autoimmunity occurs when a specific adaptive immune response of the body is 
mounted against its own healthy cells and tissues. It is usually characterized by either 
production of autoantibodies against “self” antigens by self-reactive B cells or by 
inappropriate cytotoxic T cell responses. Diseases resulting from such an aberrant 
immune response are called autoimmune diseases. Well-known examples of such 
diseases are: rheumatoid arthritis, celiac disease, lupus, hemolytic anemia, multiple 
sclerosis and type 1 diabetes (Paradowska-Gorycka et al., 2016, Kalliokoski et al., 
2016, Procaccini et al., 2016). 
 
1.4. The immune privilege of the testis 
Immune privileged sites are places in the body where “non-self” or foreign antigens are 
tolerated without evoking inflammatory immune responses. Some of these immune 
privileged sites are: the brain, the eye, the placenta, and the testis (Fijak and Meinhardt, 
2006, Fijak et al., 2011a, Amouzegar et al., 2016, Solomos and Rall, 2016, Ramhorst et 
al., 2012). 
The testis was first identified as an immune-privileged organ when histo-incompatible 
allografts (transplantation of cells, tissue or organ to a recipient from a genetically 
different donor of the same species) and xenografts (transplantation of cells, tissue or 
organ from one species to another) transplanted into the testis were observed to survive 
for an indefinite period of time (Bobzien et al., 1983, Head et al., 1983). 
In the testis, the germ cells are auto-antigenic as they express auto-reactive antigens 
(detailed in section 1.7.1). Therefore, they are protected by a special immune-privileged 
environment, which is supported by multiple mechanisms, including: 
a) The Sertoli cells provide a physical structural support of the germ cells and a 
nourishing environment by secreting the necessary nutrients and growth factors 
for the correct development of the germ cells. Moreover, Sertoli cells form the 
BTB, which provides a “wall” between germ cells and molecules coming from the 
interstitial tissue, antibodies and immune cells. 
 Introduction 
 
- 12 - 
 
b)  The expression of immunoregulatory and immunosuppressive factors by Sertoli, 
peritubular, Leydig cells and testicular macrophages as described in 
section 1.4.2. 
c) The presence of intra-testicular immune cells involved in the maintenance of the 
immune privilege as modulators of the immune response and maintaining the 
delicate equilibrium between immune privilege and inflammation by acting 
through local and systemic mechanisms. Cytokines produced by these immune 
cells play a dual role as immunosuppressors and pro-inflammatory mediators. 
The different testicular leukocytes and their function are described in detail in 
section 1.4.3. 
 
1.4.1. The blood-testis-barrier (BTB) 
The BTB, which is similar to the blood-brain-barrier or the blood-placenta-barrier, 
restricts or controls the entry of molecules or cells present in the circulation from the 
post-meiotic germ cell compartment. The BTB is formed by tight junctions located 
between adjacent Sertoli cells and is composed of claudin-11 and occludin, as well as 
gap junction proteins such as connexin 43 (McCabe et al., 2012). Inter-Sertoli cell 
junctions are the main contributors to separating the compartment containing the auto-
reactive germ cells from circulating antibodies and immune cells, allowing the creation 
of a specific environment for the appropriate development of post-meiotic germ cells 
(Haverfield et al., 2014). 
 
1.4.2. Immunoregulatory factors 
Testicular somatic cells, namely Sertoli, peritubular and Leydig cells as well as testicular 
macrophages play an important role in maintaining the immune privilege by secreting 
immunoregulatory factors.  
Sertoli cells are known to have immunosuppressive characteristics and their products 
can inhibit immune reactions (De Cesaris et al., 1992, Doyle et al., 2012, Dufour et al., 
2005). They secrete immunomodulatory factors (e.g. indolamine-2,3-dioxygenase [IDO], 
galectin-1), anti-inflammatory cytokines (e.g. transforming growth factor-1 [TGF1], 
activins) or chemokines (e.g. Chemokine (C-C motif) ligand 2 [CCL27]) (Doyle et al., 
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2012, Guazzone et al., 2009, Fijak and Meinhardt, 2006, Meinhardt and Hedger, 2011, 
Franca et al., 2016). Immunoregulatory molecules secreted by Sertoli cells, work 
together to modify the immune response and induce tolerance to protect the germ cells. 
Recently, it has been shown that peritubular cells play also a role as a component of the 
BTB by preventing immune cell entry (Rebourcet et al., 2014, Smith et al., 2015). 
Moreover, peritubular cells have been implicated in the maintenance of the testicular 
immune environment (Schuppe and Meinhardt, 2005), as they produce a number of 
cytokines, and growth factors that maintain the immune privilege, e.g. activin A (Barakat 
et al., 2008). Nonetheless, the role of peritubular cells in testicular immunity and 
inflammatory responses remain to be elucidated. 
 
1.4.3. Testicular leukocytes 
Under normal conditions, in the adult testes of most species, leucocytes are another 
prominent population of cells present in the interstitial tissue aside from Leydig cells. 
This population consists mainly of macrophages, but also dendritic cells, lymphocytes 
as well as occasional subcapsular mast cells in mice and rats (Hedger, 1997). 
 
1.4.3.1. Testicular macrophages and dendritic cells 
Mononuclear phagocytes, namely macrophages, represent a substantial cellular 
population of the interstitial tissue compartment in the testis. In mice and rats, there is 
about one macrophage for every four Leydig cells in the interstitium (Niemi et al., 1986). 
These resident macrophages have been implicated in inducing and maintaining the 
immunosuppressive microenvironment of the testis, and they have been identified as 
predominantly anti-inflammatory M2 macrophages (Hedger, 1997, Jaiswal et al., 2014). 
They are specialized in providing protection for the newly formed germ cells in the testis 
(Schuppe and Meinhardt, 2005, Fijak and Meinhardt, 2006, Hedger, 2002). Immune 
cells are identified by their specific surface markers. Mouse macrophages can be 
identified using an antibody against F4/80, a general macrophage marker (Hume et al., 
1983, Austyn and Gordon, 1981). The M1 population can be recognized by the CD86 or 
CD68 marker together with CD80 (as CD86 is also expressed on dendritic cells and 
activated T cells and CD68 is also expressed by monocytes) and M2 macrophages are 
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distinguished by expression of CD206 marker (Smith et al., 2016). Some macrophage 
surface markers provide co-stimulatory signals necessary for T cell activation. 
Moreover, dendritic cells, which are the most potent antigen presenting cells, have also 
been identified to be present in the rodent testis under normal conditions (Itoh et al., 
1995, Hoek et al., 1997). Their maturation status, including expression of co-stimulatory 
molecules, chemokine receptors and cytokines, is a key point in the induction of 
peripheral immune tolerance or autoimmunity (Bhushan and Meinhardt, 2016, Bhushan 
et al., 2015, Rival et al., 2007, Rival et al., 2006a). In fact, it is known that, the number 
of macrophages is increased under inflammatory conditions in the testis and their 
function is altered as they produce high levels of inflammatory cytokines, such as tumor 
necrosis factor (TNF) and IL-6, promoting inflammation (Rival et al., 2008, Fijak et al., 
2005, Fijak et al., 2011b, Rival et al., 2006b). 
 
1.4.3.2. T cells 
In addition to testicular macrophages and dendritic cells, T cells, namely suppressor 
CD8+ cells, NK cells and regulatory T cells, are rarely found in the normal rat and 
mouse testis, (Tompkins et al., 1998, Mukasa et al., 1995). These cells are involved in 
regulation of the immune response by increasing cellular immune surveillance and 
appear to have a reduced capacity for initiating antigen-specific immune responses in 
the adult testis (Hedger, 1997, Dai et al., 2005, Nasr et al., 2005). The cell surface 
marker known as CD3 is a T cell antigen receptor complex that plays a critical role in 
T cell activation, signaling and antigen recognition (Miescher et al., 1989, Bluestone et 
al., 1987). T cells undergo maturation in the thymus and differentiate into specific 
mature T cell subtypes and contribute to the immune tolerance as briefly described in 
section 1.3. Immature T cells in the thymus are double positive CD4+CD8+ cells. They 
lose one of these clusters after maturation and become either CD4+ T cells, which are 
usually helper T Cells, or CD8+ T cells, which usually have cytotoxic activity (Parel and 
Chizzolini, 2004). CD4+ T cells are called regulatory T cells when they express CD25 
(interleukin-2 (IL-2) receptor α-chain) and transcription factor Foxp3 (Sakaguchi et al., 
2010). Helper T cells promote cellular immunity against specific antigens, while 
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regulatory T cells suppress cellular immunity against specific antigens. The presence of 
different T cells subtypes in the inflamed testis is investigated in this study. 
 
1.5. Activin 
Activins are members of the TGF superfamily of cytokines, which are involved in the 
control of inflammation, immunity and fibrosis (Hedger et al., 2011, Phillips et al., 2009). 
In the male, activins also play a role in spermatogenesis and steroidogenesis (Young et 
al., 2015). 
 
1.5.1. Structure 
Activin A is formed as a homodimer of two A subunits of the Sertoli cell-derived 
heterodimeric hormone, inhibin, linked by a disulfide bond (Vale et al., 1986). A 
homodimer of two inhibin B subunits forms activin B, which is believed to be less 
biologically active than activin A (Nakamura et al., 1992). The subunits can also 
dimerize with an  subunit to form either inhibin A (A) or inhibin B (B). Inhibins are 
potent endogenous antagonists of activin A and B, as they block their activity by 
competing for the binding to the receptors or by reducing the availability of  subunits to 
form activin dimers (Hedger et al., 2011). Figure 6 shows the formation of activins and 
inhibins from different subunits. 
 
Figure 6: Activin and inhibin subunits. 
Activin A and B are homodimers of two A and B subunits respectively, linked by a 
disulfide bond. Inhibin A and B are heterodimers formed by the A and B subunits 
respectively, and linked by a disulfide bond to an  subunit (modified from (Hedger, 
2013). 
 Introduction 
 
- 16 - 
 
1.5.2.  Sites of production 
Activins are widely produced by both reproductive and non-reproductive tissues, with 
the testis and epididymis being the main source of activin A in the male reproductive 
tract (Barakat et al., 2008, Winnall et al., 2013, Anderson et al., 1998). Somatic and 
germ cells, in both developing and adult testes, show inhibin A and B subunit and 
activin receptor subunit gene expression (de Winter et al., 1994, Anderson et al., 1998, 
Barakat et al., 2008, Okuma et al., 2006). The expression of activins and their receptors 
by different testicular cells during fetal and post-natal life is crucial for autocrine and 
paracrine modulation of germ cell development and Sertoli cell proliferation (Barakat et 
al., 2008). In mice, inhibin , activin A and B subunit mRNAs were detected in Sertoli, 
germ and Leydig cells throughout testis development, with the A subunit also detected 
in peritubular myoid cells. The , A and B subunit proteins were detected in Sertoli 
and Leydig cells of developing and adult mouse testes (Barakat et al., 2008). Activins 
are also produced by immune cells, including activated monocytes and macrophages 
(Wang et al., 2008, Ebert et al., 2007). 
 
1.5.3. Activin signaling 
As activins are members of the TGF superfamily, they also act through a similar 
receptor-signaling pathway. The schematic signaling pathway of activins is shown in 
Figure 7. Activins bind to a type II receptor (Acvr2a or Acvr2b) on the target cell 
surface, which then recruits a type I receptor, activin-like kinase 4 (ALK4 or Acvr1b) 
specific for activin A, or ALK7 (Acvr1c) in the case of activin B. The type I receptor is a 
serine/threonine kinase which, upon recruitment, gets phosphorylated and leads to 
activation of Smad (Small body size Mothers Against Decapentaplegic) transcription 
factor signaling pathway (Logan et al., 2013, Wijayarathna and de Kretser, 2016). This, 
in turn, leads to activation or repression of Smad-regulated genes involved in 
proliferation, differentiation and survival of cells. Activins can also act via the mitogen-
activated protein (MAP) kinase signaling pathway, which is induced during inflammatory 
conditions (Hedger and de Kretser, 2013).  
Inhibins are endogenous antagonists of activin, as they lack receptor-activating activity, 
and can block activin action by competing for their receptors. More specifically, inhibins 
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bind to betaglycan, a type III TGF receptor, with high affinity, and this complex 
competes with activin for access to the type II receptor, but cannot recruit the type I 
receptors. This leads to prevention of the formation of the activin/type II receptor 
complex required for recruitment of type I receptor and initiation of the activin-signaling 
cascade (Hedger et al., 2011, Lebrun and Vale, 1997, Lewis et al., 2000). 
 
Figure 7: Activin signaling through the activin receptor signaling pathway. 
Activins A and B bind to a type II receptor that recruits a type I receptor, which gets 
phosphorylated. Activated type I receptor leads to phosphorylation of Smad2/3, which 
then forms a complex with the co-activating Smad 4. The complex translocates to the 
nucleus, binds to the DNA at specific motifs and activates the expression of target 
genes. Follistatin (FST) binds to activin and limits its access to the receptor. Inhibins, 
together with betaglycan, bind to the type II receptor, but do not recruit the type I 
receptors (Wijayarathna and de Kretser, 2016). 
 
1.5.4. Function 
Activins are involved in the HPG axis by autocrine stimulation of the secretion of FSH in 
the pituitary (Vale et al., 1986, Ling et al., 1986). In the normal adult testis, activin A 
plays a crucial role in spermatogenesis and steroidogenesis (Winnall et al., 2013, Itman 
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et al., 2006, Young et al., 2015), as the expression of activin A in Sertoli cells is 
regulated in a cyclical manner during the cycle of the seminiferous epithelium. A peak of 
activin A secretion is observed at stage VIII of the cycle of seminiferous epithelium in 
the rat testis, coinciding with spermiation (Okuma et al., 2006). Activin A is a local 
regulator of Sertoli and germ cell development, proliferation, differentiation and function 
(Nicholls et al., 2012, Mithraprabhu et al., 2010, Mendis et al., 2011). 
Furthermore, under normal conditions, activins play a role in immunoregulation, immune 
cell development and maintaining the immune privilege of the testis (Broxmeyer et al., 
1988, Hedger and Winnall, 2012). 
In a recent study, it has been shown that activin overexpression disrupts blood-testis-
barrier function in adult mice and ablates tight junction formation in differentiated rat 
Sertoli cells. Moreover, activin reinitiates Sertoli cell proliferation, which start expressing 
juvenile markers (cytokeratin-18), while suppressing the expression of mature Sertoli 
cell markers (claudin-11) (Nicholls et al., 2012).  
Moreover, dysregulation of activin A signaling can cause severe adverse effects. 
Overexpression of activin A, specifically in the testis, leads to disruption of 
spermatogenesis and infertility (Tanimoto et al., 1999), whereas chronic activin 
signaling causes reduction in testis weight and subsequent hypospermatogenesis 
(Nicholls et al., 2012).  
Furthermore, activin A has been shown to play a role in immunity, inflammation, fibrosis 
and cachexia. Activin is involved in modulating progenitor immune cell development and 
proliferation (Broxmeyer et al., 1988). Under pathological conditions, excessive activin A 
is responsible for promoting fibrosis in several tissues, such as the liver, lung, and 
kidney (Patella et al., 2006, Hedger and de Kretser, 2013). It has been shown that, in 
many acute and chronic inflammatory conditions, activin A is systemically elevated 
(Michel et al., 2003, Leto et al., 2006, Zhang et al., 2009, Yang et al., 2015, Soler 
Palacios et al., 2015). Activin A is also involved in cancer development, cell proliferation 
and migration related to cancer cell invasiveness (Le Bras et al., 2014, Heinz et al., 
2015). Activins are also the most potent negative regulators of muscle mass, as an 
increase of activin leads to a dramatic increase in muscle wasting leading to deleterious 
consequences, including increased transcription of atrophy-related ubiquitin ligases and 
 Introduction 
 
- 19 - 
 
a severe profibrotic response (Chen et al., 2016, Chen et al., 2014). In contrast to 
activin A, the physiological and pathophysiological roles of activin B in the testis and in 
inflammation/fibrosis have received little attention. 
Taken together, these data suggest that activin has important dual functions depending 
on its environment and activation status. Moreover, activin signaling needs to be strictly 
controlled in the adult testis in order to maintain Sertoli cell function, spermatogenesis, 
and integrity of the BTB, thus the immune privilege of the testis. Furthermore, the role of 
activins in regulating inflammation in the male genital tract remains to be defined. 
 
1.6. Follistatin 
Follistatin is an endogenous antagonist of activin, which binds to it with high affinity and 
blocks its action by limiting its access to the receptors (Nakamura et al., 1990). 
Therefore, follistatin plays an important role in regulating the biological activity of 
activins. 
 
1.6.1. Forms of follistatin 
Two forms of follistatin, FST288 (288 amino acids) and FST315 (315 amino acids), are 
produced by alternative splicing of the follistatin gene, FST (Shimasaki et al., 1988). 
FST288 is predominantly the tissue bound form due to its ability to bind spontaneously 
to heparan sulfate containing proteoglycans on the cell surface, whereas FST315 is 
believed to be the main circulating form, as it only binds to heparan sulfate after it has 
formed a complex with activin (Lerch et al., 2007).  
 
1.6.2. Sites of production 
Both FST288 and FST315 mRNA and protein are present in the male reproductive tract, 
with an increasing expression gradient, being lowest in the testis and highest in the vas 
deferens (Winnall et al., 2013). In the rat testis, mRNA encoding follistatin is found in 
germ cells, Sertoli cells and endothelial cells, but not in Leydig cells, whereas the 
protein is localized in spermatogonia, primary spermatocytes at all stages except the 
zygotene stage, spermatids, endothelial cells and Leydig cells (Meinhardt et al., 1998, 
Wada et al., 1996, Anderson et al., 1998). 
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1.6.3. Function and therapeutic applications 
Follistatin exerts its function indirectly by blocking activin. Follistatin is shown to induce 
muscle hypertrophy, because it also binds to myostatin, a TGFβ family cytokine 
involved in muscle development, and counters the effect of activin on muscle wasting 
and cachexia (Barbe et al., 2015). Currently, follistatin is being considered as a potential 
therapeutic target for numerous inflammatory diseases, and related fibrosis (Myllarniemi 
et al., 2014, Hardy et al., 2013, Datta-Mannan et al., 2013, Yaden et al., 2014, Rodino-
Klapac et al., 2009). 
 
1.7. Male infertility 
Infertility is one of the major health issues worldwide. As defined by the World Health 
Organization (WHO): “Infertility is the inability of a sexually active, non-contracepting 
couple to achieve pregnancy in one year” (Rowe et al., 2000). Male factors are involved 
in 45 to 50% of infertile couples (Rowe et al., 2000). Many causes of male infertility 
remain idiopathic, but several different candidates affecting the testis have been 
identified (Jungwirth et al., 2012, de Kretser, 1997). The main known etiological factors 
can be separated into the following categories:  
 untreated cryptorchidism, a common birth defect represented by the absence of 
one or both of the testes in the scrotum due to failure to descend from the 
abdominal cavity via the inguinal canal, 
 testicular cancer and, more specifically, testicular germ cell neoplasia in situ 
(GCNIS), 
 genetic disorders, such as chromosome abnormalities, with Klinefelter syndrome 
being the most frequent one, 
 varicocele, which is an enlargement of the veins of the scrotum that drain the 
testis,  
 immunological disorders, like infection and/or inflammation of the male genital 
tract, including the testis, which can be caused by trauma, viral (mumps) or 
bacterial (E. coli) infections, or sterile autoimmune inflammation. These disorders 
constitute 15% of men undergoing andrological examination in infertility clinics 
(Dohle et al., 2005, Schuppe et al., 2008, Schuppe and Bergmann, 2013). 
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Chronic testicular inflammation, known as epididymo-orchitis, is defined as an 
inflammatory lesion of one or both testes, caused by infectious or noninfectious factors 
(like trauma or chemical compounds), associated with a predominantly leukocytic 
exudate, inside and outside the seminiferous tubules, resulting in tubular damage 
(Dohle et al., 2005). The reasons for infertility are not always easy to diagnose and, 
commonly testicular inflammation might be hidden by an asymptomatic course of the 
disease (Schuppe et al., 2008). Therefore, it is crucial to explore and understand the 
mechanisms of epididymo-orchitis by using an experimental animal model. 
Furthermore, rodent models of the disease offer a tool to develop new therapeutic 
strategies. 
 
1.7.1. Experimental autoimmune epididymo-orchitis (EAEO) 
Although exceedingly rare in humans, autoimmune orchitis is a chronic inflammation of 
the testis and/or activation of the immune system against the male gametes and their 
precursor cells in the testis by production of auto-antibodies (i.e. testicular 
autoimmunity) (Dohle et al., 2005, Schuppe and Bergmann, 2013, Schuppe and 
Meinhardt, 2005, Schuppe et al., 2008).  
EAEO is a model of autoimmune based testicular inflammation that has been 
established in several experimental rodent models in order to understand the 
pathomechanisms of immunological male infertility. The disease can be induced by 
active immunization of rats and mice with homogenized testicular tissue suspended in a 
suitable adjuvant. It is an established model of testicular and epididymal inflammation 
(Tung and Teuscher, 1995, Doncel et al., 1989), leading to histopathological changes in 
the testis and a humoral and cellular immune response. The model mimics several of 
the pathological changes seen in some forms of human infertility. From studies in a rat 
model of EAEO, it is known that the disease is characterized by elevated levels of FSH, 
LH and decreased levels of testosterone in serum (Suescun et al., 1994, Fijak et al., 
2011b). It also features an increase in production of antibodies against testicular 
antigens, like heat shock proteins 60 (Hsp60) and 70 (Hsp70), disulfide isomerase 
ER-60, alpha-1-anti-trypsin, heterogeneous nuclear ribonucleoprotein H1 (hnRNP H1), 
sperm outer dense fiber major protein 2 (ODF-2), and phosphoglycerate kinase 1 (Fijak 
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et al., 2005). The disease involves increased production of inflammatory mediators, e.g. 
TNF, IL-6 and monocyte chemoattractant protein-1 (MCP-1) (Guazzone et al., 2003, 
Suescun et al., 2003, Rival et al., 2006b). Moreover, increased numbers of infiltrating 
immune cells in the testis and epididymis are observed (e.g. macrophages, dendritic 
cells, CD4+ and CD8+ T cells), leading to formation of granulomas (Jacobo et al., 2011, 
Rival et al., 2008, Aslani et al., 2015, Fijak et al., 2011b). These inflammatory events 
cause significant damage to testicular cells, leading to apoptosis of germ cells and 
varying degrees of cell sloughing, frequently resulting in subsequent aspermatogenesis 
and testicular atrophy (Aslani et al., 2015, Doncel et al., 1989). Consequently, EAEO is 
a useful model to study the pathogenesis of male testicular inflammation, and the 
physiological and immunological mechanisms that regulate its severity. 
 
Different models of EAEO induction have been documented in the literature. In general, 
experimental autoimmune orchitis has been induced using three standard protocols, as 
described in the literature: (a) induction by immunization using testicular homogenate 
(TH) and adjuvants, (b) induction by adoptive transfer of activated immune cells into 
naïve animals, or (c) by injection with viable syngeneic testicular germ cells (TGC) in 
susceptible mouse strains. The first studies describing spermatogenic impairment after 
active immunization with TH and adjuvants in guinea pig and rats date from the 1950s 
(Freund et al., 1954, Freund et al., 1953). These experiments were followed by studies 
in BALB/c, BALB/cBy and (C57BL/6 X A/J) F1 mice, where the injection of Bordetella 
pertussis extract was first introduced together with the immunization with TH and 
adjuvant (Kohno et al., 1983, Tung et al., 1987, Yule et al., 1988). This “classical” 
method of EAEO induction leads to severe histopathological changes in the testis of 
immunized animals and a strong inflammatory reaction causing infertility. 
The induction of EAEO by adoptive transfer of immune cells was reported in 1987 using 
(C57BL/6J X A/J)F1 (B6AF1) mice (Mahi-Brown et al., 1987).  
Finally the induction of orchitis by injection of TGC was performed in C3H/He, A/J mice 
(Itoh et al., 1991). This model showed altered testicular histology and significantly 
elevated mRNA levels of testicular TNF and interferon- (IFN(Terayama et al., 2011, 
Naito et al., 2012, Li et al., 2015). 
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1.8. Hypothesis and aim of the study 
Basic research about the diseases affecting male fertility in general and the testis in 
particular, has contributed to significant knowledge in this field, although still little is 
known about the mechanisms underlying many infertility disorders and, more 
specifically, chronic testicular inflammation and autoimmune orchitis. 
 
Given the collected findings from the literature that activins play an important role in 
regulating the male reproductive tract, and is increased in a number of inflammatory and 
fibrotic diseases, it was hypothesized that the activins play an important regulatory 
role during the course of testicular inflammation and have a stimulatory effect 
upon the severity of EAEO by stimulating the immunological response and 
associated damage. Blocking activin activity with exogenous follistatin could inhibit the 
disease progression, reduce the inflammation and protect spermatogenesis. 
 
The primary aim of the study was to use two mouse models: (a) adult C57BL/6N mice 
with normal levels of activin and follistatin, and (b) adult C57BL/6J mice with elevated 
systemic follistatin levels, in order to investigate the susceptibilities of these mouse 
models to EAEO development. The following parameters were investigated:  the rate of 
onset, severity and duration of testicular inflammation, spermatogenic impairment, 
immune cell composition, fibrosis and testicular dysfunction, with a particular focus on 
the expression levels of activins and activin receptors, as well as inhibin and follistatin. 
Since activin A is a potent regulator of immune cell recruitment and activity, infiltration of 
these cells into the testis and their functional status was also investigated. 
These studies will lead to an improved understanding of the development of EAEO and 
the potential involvement of activins in the process, in order to define the functional 
importance of activin as a target protein in autoimmune inflammation, genital tract 
damage and infertility, which in turn can help develop therapeutic strategies against this 
disease.  
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2. MATERIALS AND METHODS 
 
All materials, buffers, antibodies and primers used are listed in the appendix. 
 
2.1. Animals 
In vivo study I: Adult 10-12 week old C57BL/6N male mice were purchased from 
Charles River Laboratories. Animal experiments were approved by the responsible 
committee on animal care (Regierungspraesidium Giessen GI 58/2014 — Nr. 735-GP). 
In vivo study II: Adult 6 week and 10 week old C57BL/6J mice were purchased from the 
Monash Animal Research Platform (MARP) of Monash University, Clayton campus. 
Animal experiments were approved by the responsible Monash University Animal Ethics 
committee (MMCB/2015/16).  
The use of the different mouse strains in the two studies was based on the logistics of 
the different laboratories where the studies were performed. 
In vitro experiments: for the isolation of Sertoli and peritubular cells, immature 21 day 
old C57BL/6J mice were purchased from the Monash Animal Research Platform 
(MARP) of Monash University, Clayton campus.  
All experiments involving animals were carried out in strict accordance with the 
recommendations of the Guide for the Care and Use of Laboratory Animals of the 
German law of animal welfare and with the requirements from the Australian Code for 
the Care and Use of Animals for Scientific Purposes, 8th Edition 2013 (the Code) and 
relevant Victorian legislation. 
The animals were housed under specific-pathogen-free (SPF) conditions (12 hours 
light/dark cycle, 20~22°C), with access to water and food ad libitum.  
Mice received analgesia in a form of Tramadol (STADApharm GmbH, Bad Vilbel, 
Germany) in drinking water (2.5 mg/ml) starting 24 hours before each immunization and 
kept for the following 3 days. During immunization, animals were anesthetized by 
inhalation of 3-5% isoflurane and all efforts were made to minimize suffering. For 
euthanasia, animals were deeply anesthetized by inhalation of 5% isoflurane and 
sacrificed by cervical dislocation. 
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2.2. Human testicular biopsies 
Bouin’s fixed and paraffin-embedded human testicular biopsies were provided by the 
Giessen Testicular Biopsy Repository, (Profs. Hans-Christian Schuppe, Martin 
Bergmann). The specimens were obtained from infertile men with non-obstructive 
azoospermia and a histological diagnosis of focal inflammatory lesions associated with 
disturbed spermatogenesis (Schuppe and Bergmann, 2013). Biopsies from patients with 
obstructive azoospermia, i.e. intact spermatogenesis without any signs of inflammation, 
served as control. From all men undergoing testicular biopsy, written informed consent 
was obtained. The study was approved by the local institutional review board (Ref.No. 
100/07). 
 
2.3. Induction of EAEO  
In order to induce EAEO, adult male C57BL6/N or C57BL/6J mice aged 10-12 weeks 
were actively immunized with syngeneic testicular homogenate as described in a rat 
model (Doncel et al., 1989, Aslani et al., 2015, Fijak et al., 2011b), with some 
modifications. The testicular homogenate (TH) was prepared from testes collected from 
C57BL/6N or C57BL/6J mice. After removal of the tunica albuginea, the testes were 
homogenized by Potter S homogenizer in sterile 0.9% NaCl at a ratio of 1:1. Animals 
were immunized 2 or 3 times, every 14 days by using testicular homogenate mixed with 
either Freund’s adjuvant or TiterMaxGold adjuvant at a ratio 1:1, followed by i.p. 
injection of 100 ng Bordetella pertussis toxin (Calbiochem, Germany) in 100 µl Munõz 
Buffer (Kohno et al., 1983). Each animal was immunized by four s.c. injections with a 
total volume of 200 µl (50 µl per side of injection). The animals were injected on the 
back in the area of the shoulders and the hind limbs in the proximity of the lymph nodes. 
Adjuvant control animals received respective adjuvant mixed with 0.9 % NaCl instead of 
testicular homogenate followed by i.p. injection of 100 ng B. pertussis toxin, as above. 
In the current studies, the following adjuvants were used: complete Freund’s adjuvant 
(CFA) containing killed Mycobacterium tuberculosis, incomplete Freund’s adjuvant (IFA) 
or TiterMaxGold adjuvant (all from Sigma-Aldrich, St Louis, USA). Age-matched 
untreated mice were also included. 
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Animals were divided into 5 groups in two separate studies (Study I and Study II) and a 
schematic of the treatment groups and time-line of the injections is shown below in 
Figures 8 - 12. The immunization protocol in Study II was modified according to the 
Monash University Animal Ethics committee requirements regarding the use of the 
adjuvants. 
 
Study I: 
 
Figure 8: Schematic diagram illustrating the time course of immunizations for the 
induction of EAEO in C57BL/6N mice from study I, group I. 
Mice received three subcutaneous injections of either testicular homogenate (TH; EAEO 
group) or saline (adjuvant control group) mixed with CFA (complete Freund’s adjuvant) 
at ratio 1:1, every 14 days. Each immunization was followed by an i.p. injection of Bp 
(Bordetella pertussis) toxin. Mice were killed at 30, 50 and 80 days after the first 
immunization and testes and blood were collected.  
 
 
Figure 9: Schematic diagram illustrating the time course of immunizations for the 
induction of EAEO in C57BL/6N mice from study I, group II. 
Mice received three subcutaneous injections of either testicular homogenate (TH; EAEO 
group) or saline (adjuvant control group) mixed with TiterMax Gold adjuvant at ratio 1:1, 
every 14 days. Each immunization was followed by an i.p. injection of Bp (Bordetella 
pertussis) toxin. Mice were killed at 50 and 80 days after the first immunization and 
testes and blood were collected. 
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Figure 10: Schematic diagram illustrating the time course of immunizations for 
the induction of EAEO in C57BL/6N mice from study I, group III. 
Mice received two subcutaneous injections of either testicular homogenate (TH, EAEO 
group) or saline (adjuvant control group) mixed with TiterMax Gold adjuvant at ratio 1:1, 
every 14 days. Each immunization was followed by an i.p. injection of Bp (Bordetella 
pertussis) toxin. Mice were killed at 50 and 80 days after the first immunization and 
testes and blood were collected.  
 
Study II: 
 
Figure 11: Schematic diagram illustrating the time course of treatments and 
immunizations for the induction of EAEO in C57BL/6J mice from study II, group 
IV. 
Mice received an intramuscular injection of 1.2 x 1010 empty rAAV (recombinant 
adenovirus-associated viral vector) (EV group) in the tibialis anterior 30 days prior to the 
first immunization, then three subcutaneous injections of either testicular homogenate 
(TH; EAEO group) or saline (adjuvant control group) mixed with an adjuvant at ratio 1:1, 
every 14 days. CFA was used for the first immunization and IFA was used for the two 
following immunizations. Each immunization was followed by an i.p. injection of Bp 
(Bordetella pertussis) toxin. Mice were killed at 30 and 50 days after the first 
immunization. Testes and blood were collected. 
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Figure 12: Schematic diagram illustrating the time course of treatments and 
immunizations for the induction of EAEO in C57BL/6J mice from study II, group V. 
Mice received an intramuscular injection of 1.2 x 1010 rAAV (recombinant adenovirus-
associated viral vector) carrying a gene cassette of the circulating FST315 form of 
follistatin (FST group), in the tibialis anterior, 30 days prior to the first immunization, then 
three subcutaneous injections of either testicular homogenate (TH; EAEO group) or 
saline (adjuvant control group) mixed with an adjuvant at ratio 1:1, every 14 days. CFA 
was used for the first immunization and IFA was used for the two following 
immunizations. Each immunization was followed by an i.p. injection of Bp (Bordetella 
pertussis) toxin. Mice were killed at 30 and 50 days after the first immunization. Testes 
and blood were collected. 
 
Experimental endpoints were selected based on previous EAEO studies described in 
the literature. Thirty, fifty and/or eighty days after the first immunization, animals were 
sacrificed and blood was collected by cardiac puncture and the testes were removed. 
After clotting, the blood was centrifuged at 1000 x g for 15 minutes at 4°C and sera 
were stored at -80°C for further analysis. The testes were weighed, and either snap-
frozen in liquid nitrogen or fixed in Bouin’s solution and embedded in paraffin. For flow 
cytometric analysis, fresh testes were used. 
 
2.4. Therapeutical elevation of circulating follistatin levels in 
mice 
In order to investigate the effects of increased follistatin levels during the course of 
testicular inflammation, follistatin was over-expressed in adult wild-type C57BL/6J mice 
at 6 weeks of age, by transfection of leg muscle cells with a non-replicative recombinant 
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adenovirus-associated viral vector (rAAV) carrying a gene cassette of the circulating 
FST315 form of follistatin (rAAV-FST315) (in collaboration with Dr. Justin Chen and Dr. 
Paul Gregorevic, Baker IDI, Melbourne, Australia). The rAAV vector consists of a 
sequence of DNA, therefore it is not a virus, is not replicative and is not infectious. 
Typically, mice transfected with these vectors express the target protein at a level 
proportional to the transfection dose (Hagg et al., 2016, Chen et al., 2014, Winbanks et 
al., 2012, Nicholls et al., 2012).  
The vector carrying the follistatin gene (rAAV-FST315) and an empty control vector 
(rAAV) were administered to adult 6 week old male mice in study II, in the form of a 
single i.m. injection into the right tibialis anterior muscle at a dose of 1.2 x 1010 vector 
genomes in a volume of 5 µl saline. The vector becomes integrated into the muscle 
cells and acts as a production reservoir, leading to elevated levels of the protein 
encoded by the vector. Control mice received the viral vector with an empty expression 
cassette. The injections were performed under specific-pathogen-free (SPF) conditions 
in the Monash Medical Centre animal house by Dr. Chen. To monitor the levels of 
follistatin in serum from treated animals, a radioimmunoassay was performed (detailed 
explained in paragraph 2.11.4). 
 
2.5. Biotin tracer study for analysis of the integrity of the blood-
testis-barrier 
In order to assess the integrity of the blood-testis-barrier (BTB) in mouse testes, an 
NHS-linked biotin tracer was perfused into the testes by immersion as follows: after 
collection of the testis, a hole in the tunica albuginea was performed by a needle 
puncture. Afterwards the testes were immersed in NHS-linked biotin (10 mg/ml in PBS 
with 10 mM CaCl2; EZ-Link® Sulfo-NHS-LC-Biotin; Thermoscientific, Rockford, USA) 
and incubated for 30 min at room temperature (RT) (Meng et al., 2005, McCabe et al., 
2012). As the tracer is incorporated in the testis, it binds covalently to every amine 
(-NH2) group on every protein that it encounters. Each protein bound to the tracer is 
now biotinylated and can be detected by immunohistochemistry. After incubation in the 
tracer, the testes were removed from the solution and fixed in Bouin’s solution for 5 
hours and further processed for paraffin-embedding. 
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2.6. Paraffin-embedding 
Collected testes were weighed, and then fixed in Bouin’s solution for 5 hours. Bouin’s 
solution was freshly prepared from 75 ml picric acid, 25 ml formaldehyde solution (37%) 
and 5 ml acetic acid. After fixation, samples were dehydrated in increasing ethanol 
series starting from 70% and followed by 96% and 100%. The solutions were changed 
several times and the organs were kept for minimum 2 hours in each concentration of 
ethanol. Testes were then transferred into pure benzoic acid methyl ester (>99%) (Carl 
Roth, Karlsruhe, Germany) for 2 hours and finally in xylol for 2 hours before transferring 
them into a mixture of xylol and paraffin (1:1) for one hour at 60°C. Finally, the organ 
samples were transferred to pre-warmed liquid paraffin at 60°C overnight. On the 
following day, the testes were embedded in paraffin. 
 
2.7. Histochemistry 
 
2.7.1. Periodic acid Schiff (PAS) staining  
PAS staining is a widely used histological stain as it allows the identification of different 
tissue constituents such as polysaccharides (i.e. glycogen) and mycosubstances (i.e. 
glycoproteins and glycolipids) (Niakani et al., 2013, Ahmed and de Rooij, 2009). Bouin’s 
fixed, paraffin-embedded testis samples were cut on the microtome (Leica, Mount 
Waverly, Australia) at a thickness of 5 μm and mounted on SuperFrost Plus 
microscope slides (R. Langenbrinck, Emmendingen, Germany). The sections were 
de-paraffinized in xylene, rehydrated through a series of decreasing ethanol 
concentrations ranging from 100% to 50%, and rinsed in distilled water. Tissue sections 
were oxidized in 1% periodic acid solution (Amber Scientific, Midvale, Australia) for 5 
min, rinsed and placed in Schiff’s reagent (37% formalin and a few drops of Schiff’s 
reagent [Amber Scientific, Midvale, Australia]) for 10 min. Afterwards, they were washed 
in tap water for 10 min and counterstained in Harris’s hematoxylin solution (Sigma, St 
Louis, USA) for 5 min, washed again, dehydrated in a series of increasing ethanol 
concentrations ranging from 50% to 100% and cleared in xylene. Finally, sections were 
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mounted with coverslips using DPX mounting medium and glass coverslips (Merck, 
Darmstadt, Germany). 
 
2.7.2. Azo-carmine and aniline blue (azan) staining 
Azan staining is used for evaluation of the fibrotic response as it stains the collagen 
fibers blue and connective tissue red (Carvajal Monroy et al., 2015, Kikui and Miki, 
1995).  
5 µm thin paraffin sections were de-paraffinized in xylene, rehydrated through a series 
of decreasing ethanol concentrations as described previously, rinsed in distilled water 
and then stained in aniline alcohol (0.1% aniline oil [VWR, Fontenay-sous-Bois, France] 
in 90% ethanol). Afterwards, sections were dyed with preheated 0.1% azo-carmine G 
solution (Chroma-Gesellschaft, Stuttgart, Germany), 1% glacial acetic acid (Merck, 
Darmstadt, Germany), rinsed in distilled water and nuclei were differentiated in aniline 
alcohol. Afterwards, connective tissue was stained for 2 hours in 5% phosphotungstic 
acid. Sections were rinsed with distilled water and then stained for 2 hours in aniline 
blue-orange mixture (0.5% aniline blue [Merck], 2% Orange G [Merck], 8% glacial citric 
acid). Differentiation was performed in 96% ethanol until tissue constituents emerged. 
Subsequently the sections were dehydrated in isopropanol, treated with xylene and 
mounted in Eukitt Quick hardening mounting medium (Sigma-Aldrich, Saint Louis, USA) 
using glass coverslips. 
 
2.7.3. Masson’s trichrome staining 
Masson’s trichrome staining, like azan staining, is one of the most widely used 
trichrome stains for examining collagen deposition within tissue (Hong et al., 2016, 
Michel et al., 2016). 5 µm thin paraffin sections were de-paraffinized in xylene, 
rehydrated through a series of decreasing ethanol concentrations as described 
previously, rinsed and stained for 5 min in celestin blue (5% ferric ammonium sulfate 
[Ajax Finechem, Seven Hills, Australia], 0.5% celestin blue [Merck, Poole, UK],  14% 
glycerin [Ajax Finechem] in distilled water). Sections were then washed in tap water and 
placed in Weigert’s iron hematoxylin (1% hematoxylin [Sigma] in ethanol, 1.15% ferric 
chloride [Ajax Finechem], 1% concentrated hydrochloric acid [Merck, Munich, Germany] 
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in distilled water) for 30 min, then washed again in running tap water. Tissue 
components were differentiated briefly in acid alcohol (0.5% concentrated hydrochloric 
acid [Merck] in 70% ethanol). Sections were washed in running tap water for 10 min and 
stained with Biebrich scarlet-acid fuchsin (0.9% Biebrich scarlet [Merck], 0.1% acid 
fuchsin [Merck], 1% glacial acetic acid [Merck] in distilled water) for 5 min. 5% aqueous 
phosphotungstic acid (Ajax Finechem) was applied for 5 min after washing briefly with 
distilled water and then washed again before the sections were stained in aniline blue 
staining solution (2.5% aniline blue [Merck], 2.5% glacial acetic acid [Merck] in distiller 
water) for 5 min. Finally, sections were washed in 1% aqueous acetic acid (Merck) for 3 
min, dehydrated in a series of increasing ethanol concentrations ranging from 50% to 
100%, cleared in xylene and cover slipped using DPX mounting medium. 
 
2.7.4. Toluidine blue staining of mast cells 
Mast cells are found in the connective tissue and their cytoplasm contains granules 
composed of heparin and histamine (Wernersson and Pejler, 2014). Toluidine blue 
stains mast cell granules red-purple (metachromatic staining) and the cytoplasm blue 
(orthochromatic staining). Metachromasia is the property of certain tissue elements to 
be stained in a different color from the dye solution, due to the pH, dye concentration 
and temperature of the basic dye. Blue and violet dyes will show a red color shift, and 
red dyes will show a yellow color shift with metachromatic tissue elements. Toluidine 
blue staining was performed as described previously (Iosub et al., 2006). Briefly, 5 µm 
thin paraffin sections were de-paraffinized in xylene, rehydrated through a series of 
decreasing ethanol concentrations as described above, rinsed and stained in toluidine 
blue working solution (10% of the 1% toluidine stock solution in 0.5% sodium chloride). 
Sections were then washed in distilled water, dehydrated in 95% and 100% ethanol, 
cleared in xylene and cover slipped using Entellan® new mounting medium (Merck, 
Darmstadt, Germany). 
 
2.7.5. Proliferating cell nuclear antigen (PCNA) staining 
PCNA staining is commonly used to detect cell’s proliferative ability (Wu et al., 2016, 
Hall et al., 1990). After de-paraffinization in xylol and rehydration in 100% ethanol, 5 µm 
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thin paraffin testicular sections were incubated for 30 min in 4% H2O2 in methanol 
solution in order to block endogenous peroxidase activity. Sections were then placed in 
96% followed by 70% ethanol and washed with distilled water and PBS. Subsequently, 
sections were incubated for 1 hour at RT with the mouse monoclonal anti-PCNA, 
IgG2a, Clone PC10 (M0879, Dako, Glostrup, Denmark) diluted 1:500 in PBS, washed 
and incubated again in undiluted HRP-labeled polymer conjugated to goat anti-rabbit 
immunoglobulins (K4003, Dako, Glostrup, Denmark) for 30 min at RT. Sections were 
then washed in PBS and the colorimetric reaction was developed by using 
diaminobenzidine (DAB) (DAKO, Carpinteria, CA, USA) under the microscope. Finally, 
slides were washed in distilled water, dehydrated in a series of increasing ethanol 
concentrations ranging from 70% to 100%, cleared in xylene and cover slipped using 
Entellan® new mounting medium. 
 
2.7.6. TUNEL staining of apoptotic cells 
Terminal deoxynucleotidyl transferase (TdT) dUTP Nick-End Labeling (TUNEL) staining 
is performed in order to detect apoptotic cells that undergo extensive DNA degradation 
during the late stages of apoptosis (Arguello et al., 1998, Carmeliet et al., 1998). The 
staining was performed using the ApopTag® Peroxidase In Situ Apoptosis Detection Kit 
(S7100, Merck, Darmstadt, Germany). The method is based on the ability of TdT to 
label blunt ends of DNA strand breaks that are detected by enzymatic labeling of free 
3’-OH termini with modified nucleotides (Gavrieli et al., 1992, Schmitz et al., 1991). 
These new DNA ends generated upon DNA fragmentation are typically localized in 
morphologically identifiable nuclei and apoptotic bodies. In contrast, normal or 
proliferative nuclei, which have relatively low numbers of DNA 3'-OH ends, usually do 
not stain. The TUNEL staining detects single-stranded and double-stranded breaks 
associated with apoptosis (McGahon et al., 1994). The procedure was performed as 
follows: 5 µm thin paraffin testis sections were de-paraffinized in xylene, rehydrated in 
100% and 70% ethanol and washed in PBS. Sections were covered and incubated with 
the provided equilibration buffer for 10 min at RT. 30 µl of the TdT enzyme was diluted 
in 70 µl of the reaction buffer. Sections were incubated with the TdT enzyme, while 
specimens for a negative control were covered with PBS only and incubated for 1 hour 
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at 37°C. In the meantime, the supplied stop buffer was prepared at 1:34 ratio in distilled 
water and pre-heated at 37°C. Sections were then immersed in the stop/wash buffer for 
30 min at 37°C, washed with PBS and then quenched in 3% H2O2 in PBS for 15 min in 
the dark in order to block endogenous peroxidases. After washing twice with PBS, 
sections were covered with 100 µl of CAS block reagent (Life Technologies, Frederick, 
MD, USA) and incubated for 30 min at RT, then with 30 µl of the provided anti-dig 
peroxidase for 30 min at RT. Finally, sections were washed in PBS and the colorimetric 
reaction was developed by using DAB. Sections were counterstained with hematoxylin, 
washed in water and dehydrated in 70% and 100% ethanol, cleared in xylene and 
coverslips were mounted on slides using DPX mounting medium. 
 
2.8. Immunofluorescence microscopy 
 
2.8.1. Immunofluorescence staining of testicular macrophages 
A double staining of F4/80 (general macrophage marker) and CD206 (a mannose 
receptor, marker of M2 macrophages) was performed on 8 μm thin testis cryosections 
fixed in 4% paraformaldehyde (Merck, Darmstadt, Germany) for 10 min, washed in 
TBST (Tris buffered saline with 0.1% Tween 20) and blocked for one hour in 10% 
normal goat serum (Dako, Glostrup, Denmark) diluted in TBST at RT. Sections were 
then stained using MaxFluorTM Rat on Mouse Fluorescence Detection Kit (MaxFluor 
488) (MaxVision Biosciences Inc., Washington, USA) according to the manufacturer’s 
protocol. Briefly, sections were incubated in serum-free blocker for 10 min followed by 
overnight incubation with rat anti-mouse F4/80 (MCA497G, AbD Serotec, Kidlington, 
UK) and rabbit anti-mouse CD206 (mannose receptor) (ab64693, Abcam, Cambridge, 
UK) antibodies diluted 1:100 and 1:200, respectively, in 1% normal goat serum diluted 
in TBST at 4°C. Subsequently, slides were washed and incubated in rat signal amplifier 
(MaxVision) for 30 min, followed by incubation with MaxFluor488 labeled linker 
(MaxVision) for 1 hour, and finally washed and incubated for one hour with F(ab’)2-goat 
anti-rabbit IgG (H+L) AlexaFluor546 (A11071, Life Technologies, Carlsbad, USA) 
diluted 1:1000 in 1% normal goat serum diluted in TBST. Glass coverslips were 
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mounted on slides with ProLong Gold Antifade mountant with 4',6-diamidino-2-
phenylindole (DAPI) (Life Technologies, USA). 
 
2.8.2. Activin A immunofluorescence staining  
In order to detect the localization of activin A protein in the testis, immunofluorescence 
staining was performed (Barakat et al., 2008). After de-paraffinization and rehydration, 
5 µm thin paraffin sections were rinsed in distilled water and placed in TBST. Sections 
were then boiled in the microwave for antigen retrieval in citrate buffer (10 mM, pH 6.0) 
for 6 min at full power, left to cool down and washed in TBST.  
Afterwards sections were stained following the manufacturer’s instructions included in 
the MaxFluorTM Mouse on Mouse Fluorescence Detection Kit (MaxFluor 488) 
(MaxVision Biosciences Inc. Washington, USA). Briefly, sections were blocked with a 
drop of the ready to use protein blocking solution for 10 min, then with the MaxMOMTM 
blocking reagent for 1 hour. Sections were washed and incubated with the E4 antibody 
(mouse anti-activin A, 1.3 mg/ml, supplied by Oxford-Brooks University, Oxford, UK) 
diluted 1:200 in TBST and incubated overnight at 4°C. Sections were then washed and 
incubated with the Fluorescence Signal Enhancer for 30 min, washed again and 
incubated for 1 hour with the MaxFluor 488 labeled linker concentrate diluted 1:400 in 
the fluorescent diluent. Finally, slides were washed and mounted with coverslips and 
ProLong Gold Antifade mountant with DAPI. 
 
2.8.3. Alpha smooth muscle actin (α-SMA) immunofluorescence staining 
In order to detect the localization and distribution of the -smooth muscle actin layer 
within the testicular peritubular cells, immunofluorescence staining was performed on 
testis sections. 5 µm thin paraffin sections were de-paraffinized, rehydrated, rinsed in 
distilled water and TBST then boiled for antigen retrieval in citrate buffer (pH 6.0) for 
6 min in the microwave at full power, left to cool down and washed in TBST. Sections 
were then incubated overnight with the mouse monoclonal FITC conjugated anti -  
smooth muscle actin antibody (F3777, Sigma, St Louis, USA) diluted 1:1000 in TBST. 
Subsequently, slides were washed and mounted in ProLong Gold Antifade mountant 
with DAPI. 
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2.8.4. Immunofluorescence staining for detection of the integrity of the 
BTB 
In order to detect the integrity of the BTB and assess its disruption during the 
development of EAEO, immunofluorescence staining of the NHS-linked biotin tracer 
was performed (McCabe et al., 2012, Meng et al., 2005, Perez et al., 2012). 
5 µm thin paraffin sections were de-paraffinized, rehydrated, rinsed in distilled water 
then incubated for 1 hour with streptavidin - AlexaFluor488 conjugate (S32354, Life 
Technologies, Carlsbad, USA) diluted 1:500 in PBS. Slides were then mounted in 
VECTASHIELD® Antifade mounting medium with DAPI (Vector, Burlingame, USA). 
 
2.8.5. Evaluation of Sertoli and peritubular cells purity by α-SMA and Sox9 
double staining  
In order to estimate the purity of isolated Sertoli and peritubular cells, an 
immunofluorescence staining was performed using a Sertoli cell marker, Sox9 (SRY-
box9) and a peritubular cell marker, SMA. At 24 hours after the hypotonic shock 
treatment, cultured Sertoli and peritubular cells in 8 well slides, were washed with PBS 
and fixed for 10 min in 4% PFA. Afterwards, cells were permeabilized in 0.1% Triton X 
and blocked for one hour with 10% normal goat serum in TBST. Cells were then 
washed in TBST and incubated overnight with the mouse monoclonal FITC conjugated 
anti -  smooth muscle actin antibody (F3777, Sigma, Saint Louis, USA) diluted 1:1000 
in 1% normal goat serum in TBST followed by incubation with rabbit polyclonal anti-
Sox9 antibody (sc-20095, Santa Cruz Biotechnology, Dallas, USA) diluted 1:100 in 1% 
normal goat serum in TBST. Cells were then washed and incubated with secondary 
goat anti-rabbit IgG (H+L) Alexa Fluor® 594 conjugate for 1 hour in the dark. Finally, 
cells were washed twice with TBST, and slides were mounted with a drop of 
VECTASHIELD® Antifade mounting medium with DAPI. 
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2.9. Flow cytometric analysis of T cells 
All incubation steps were conducted at 4°C for 30 min. Briefly, a maximum of 1 x 106 
interstitial cells were incubated with mouse FcR blocking reagent (Miltenyi Biotech, 
Bergisch-Gladbach, Germany) for 10 min at 4°C. After blocking, the following 
monoclonal antibodies (all from Miltenyi Biotec) were used: rat anti-mouse CD45-
VioBlue (clone 30F11.1), hamster anti-mouse CD3ɛ-APC (clone 145-2C11), rat anti-
mouse CD4-APC-Vio770 (clone GK1.5), rat anti-mouse CD8a-PE-Vio770 (clone 53-6.7) 
and rat anti-mouse CD25-PE (clone 7D4). Background staining was evaluated using 
appropriate isotype controls: rat IgG2b-VioBlue, rat IgG2b-APC-Vio770, rat IgG2a-PE-
Vio770, rat IgM-PE (all from Miltenyi Biotec) and hamster IgG1-APC (eBioscience, San 
Diego, USA). Afterwards cells were rinsed with washing buffer (PBS, 0.5% BSA, 2mM 
EDTA). Data were collected for 300,000 events using a MACS Quant Analyzer 10 flow 
cytometer (Miltenyi Biotech, Bergisch-Gladbach, Germany) and analyzed with FlowJo 
software version 10.0.8 (Ashland, Oregon, USA). The gating strategy is presented in 
Figure 13: After gating out debris, doublets, and nonviable cells (Fig. 13a, b and c), 
immuno-labeled CD45+ cells were gated (Fig. 13d). For further analysis, CD3+ cells 
(Fig. 13e) were selected within the CD45+ gate and then several T cell subtypes, 
namely CD4+, CD8+ as well as CD4+CD25+ and CD4+CD8+ cells were gated within 
CD3+ cells (Fig. 13 f and g). All flow cytometry measurements and analysis were 
performed by Dr. Monika Fijak. 
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Figure 13: Representative dot plots showing the gating strategy for flow 
cytometric analysis of testicular immune cells. 
Detected cells were plotted using a forward (FSC) and a side scatter (SSC) (a). 
Doublets (b), cell debris and non-viable cells (c) were gated out. CD45+ cells were 
selected from singlets and viable cells (d). CD3+ cells (e) were gated out from CD45+ 
cells, and then CD4+CD8-, CD4-CD8+ as well as CD4+CD25+ (f) and CD4+CD8+ (g) T 
cells were selected from CD3+ T cell population (courtesy of Dr. Monika Fijak). 
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2.10. Analysis of gene expression by quantitative RT-PCR 
 
2.10.1. RNA isolation 
Total RNA was isolated from frozen mouse testes using RNeasy Mini kit (Qiagen, 
Hilden, Germany) according to the manufacturer’s instructions. Briefly, about 20 mg of 
each testis was cut and homogenized with 350 μl RLT Lysis buffer containing 1% -
mercaptoethanol either with a Potter S or using stainless steel beads and a tissue lyser 
(Qiagen, Hilden, Germany) at 40 oscillations/second for a minimum of 1 min. Lysates 
were collected after centrifugation for 3 min at 14,000 x g, and equal volume of 70% 
ethanol was added, mixed well, and then transferred to and RNeasy mini spin column. 
Columns were centrifuged at 10,000 x g for 1 min and washed once with RW1 wash 
buffer. On column DNase I treatment (Qiagen, Hilden, Germany) was performed to 
digest genomic DNA (gDNA) as follows: 10 μl DNase I stock solution was added to 70 
μl provided RDD buffer. Afterwards, 80 μl of the DNase solution was administered to the 
column and incubated for 30 min at RT. Columns were washed once more with RW1 
buffer followed by washing with RPE buffer containing 90% ethanol to precipitate RNA 
and dried by centrifugation for 2 min at 14,000 x g. RNA was eluted in 50 μl RNase free 
water, pre-warmed at 65°C. 
RNA concentrations were quantified using the NanoDrop ND2000 (Promega, 
Mannheim, Germany). The yield of RNA concentration obtained was approximately 
1 µg/µl with highly pure RNA based on the 260/280 and 260/230 wavelength ratios, 
which were around 2, indicating no contamination with proteins, phenols, carbohydrates 
or other compounds that might interfere. 
 
2.10.2. Test for presence of genomic DNA contamination  
 
2.10.2.1. B-actin amplification 
The absence of gDNA was confirmed by amplification of -actin (actb) transcript using 
an isolated RNA sample as a template. 1 µl of RNA was added to a master mix 
(Promega) containing 5 µl of 5x green Go Taq Flexi buffer, 2 µl MgCl2 (25 mM), 0.5 µl 
dNTPs (10 mM), 0.25 µl Go Taq Flexi polymerase and 0.5 µl of each -actin forward 
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and reverse primer (10 pM each) in 15.25 µl distilled water. RT-PCR was run on a PCR 
thermocycler (PeqLab, Erlangen, Germany) for 25 cycles as shown in Table 1. 
 
Table 1: RT-PCR program for -actin amplification. 
 
 
2.10.2.2. DNA agarose gel electrophoresis 
1.5% agarose gels were prepared by dissolving 1.5 g of agarose in 1x TAE buffer. After 
cooling, ethidium bromide (0.5 μg/ml) was added to the agarose solution and gels were 
casted. Samples were loaded next to a 100 bp DNA ladder (Promega, Mannheim, 
Germany). Gels were run at 110 V (2-10 V/cm gel). Finally, agarose gels were 
examined on a UV transilluminator and photographed using a gel jet imager 2000 
documentation system (Intas, Göttingen, Germany). cDNA used as positive control 
showed a band with a -actin transcript at the expected size of 156 bp. Negative control 
with RNase free water as template and RNA samples showed no bands. 
 
2.10.3. Reverse transcription (RT) by PCR 
For study I (group I), reverse transcription was performed using 1 µg RNA sample 
mixed with 2 µl Oligo (dT) 15 Primer (Promega, Mannheim, Germany) in a total volume 
of 18 µl and denatured at 70°C for 10 min. RT master mix (Promega) containing 8 µl of 
5x RT buffer, 2 µl of 10mM PCR nucleotide mix, 1 µl of recombinant RNasin 
ribonuclease inhibitor, and 18 µl of RNase free water was pre-warmed at 42°C. Finally, 
denatured RNA was mixed with the RT master mix before adding 1 µl of M-MLV reverse 
transcriptase, RNase (H-), point mutant (Promega) to each sample and reverse 
transcribed at 42°C for 75 min. Afterwards, the enzyme was inactivated at 72°C for 15 
min and cDNA samples were store at -20°C for further use. 
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In study II, RNA from testes of animals from groups IV and V was reverse transcribed 
by using 800 ng RNA mixed with 1 µl of random hexamers (50 ng/µl) (Invitrogen, 
Carlsbad, USA) and 1 µl of dNTPs (10 mM) (Invitrogen), then denatured at 65°C for 5 
min. RT master mix (Invitrogen) containing 2 µl of 10x RT buffer, 4 µl of MgCl2 (25 mM), 
2 µl of DTT (0.1 M), 1 µl of RNaseOUT (40 U/µl) and 1 µl of superscript III reverse 
transcriptase (200 U/µl) was prepared and added to each sample. The mixture was kept 
at 25°C for 10 min then heated to 50°C for 50 min, and finally for 5 min at 85°C. 
Afterwards, 1 µl of E. Coli RNase H (2 U/µl) was added to each sample and incubated 
at 37°C for 20 min. Finally, cDNA samples were stored at -20°C for further use.  
Genomic DNA contamination of RNA samples was checked following the same 
procedure as for the reverse transcription, but with omitting the superscript III RT 
(200 U/µl) from the RT master mix and by verifying that there was no amplified PCR 
product for the specific gene after RT-PCR. 
 
2.10.4. Quantitative RT-PCR 
Quantitative RT-PCR is a technique used in order to monitor and quantify the 
amplification of a target gene under real time conditions by polymerase chain reaction 
(PCR). The quantity of the specific gene can be either an absolute number of copies or 
a relative amount when normalized to housekeeping genes. Fluorescent dyes (SYBR 
green) that intercalate with the double stranded DNA are used for the detection of the 
PCR products in real-time (Bustin et al., 2009).  
For study I, quantitative RT-PCR was performed using CFX TouchTM Real-Time PCR 
detection system (Bio-Rad, Munich, Germany). 
For the evaluation of Inhba, Inhbb, Inha, Acvr1b, Acvr2b, Fst, Fst288 and Fst315 mRNA 
expression, iTaq Universal SYBR Green Supermix (Bio-Rad) was used as described in 
Table 2. QuantiTect SYBR green PCR Master Mix and QuantiTect primer assay 
(Qiagen) were used to evaluate IL-6, IL-10, Ccl2 and Tnf mRNA expression. The 
reaction mix is described in Table 2. 
For study II, the evaluation of all the above mentioned genes was performed using 
Power SYBR green PCR master mix (Applied Biosystems, Warrington, UK) on Fast 
 Materials and methods 
 
- 42 - 
 
Real-Time PCR system (Applied Biosystems, Forest City, USA). The reaction mix is 
described in Table 2. 
 
Table 2: Quantitative RT-PCR reaction mixes. 
  
 
All primers used are listed in Table 7 in the appendix. Relative gene expression was 
calculated using the 2-Ct method (Livak and Schmittgen, 2001) and normalized to 
three housekeeping genes (B2M [2-microglobulin], HPRT [hypoxanthine guanine 
phosphoribosyl transferase] and 18S rRNA) used as internal controls for samples from 
study I, or normalized to two housekeeping genes (HPRT and 18S rRNA) used as 
internal controls for samples from study II. Briefly, the 2-Ct method is based on 
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calculation of Ct by subtracting the Ct value of the housekeeping gene from the Ct 
value of the amplified gene in a sample. Ct is then calculated by subtracting the Ct 
value of each sample to the mean of the control samples. Finally, 2-Ct represents the 
relative expression of the gene. Quantitative RT-PCR programs are described in 
Table 3. 
 
Table 3: Quantitative RT-PCR programs.  
 
 
A melt curve analysis was also performed in parallel with the relative gene expression, 
allowing the assessment of the dissociation characteristics of double-
stranded DNA during heating. As the temperature is raised, the double DNA strand 
starts to dissociate leading to the release of the intercalating SYBR green fluorescent 
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dye and therefore a decrease of the emitted fluorescent signal. The change in slope of 
the fluorescence curve is then plotted as a function of temperature to obtain the melt 
curve. Analysis of the melt curve allows assessing whether the quantitative RT-PCR 
assay has produced one single specific product during the amplification of the target 
gene. A single peak shown by the melt curve represents one single amplicon. Figure 14 
shows a representative melt curve for all the studied transcripts. 
 
Figure 14: Representative melt curves from quantitative RT-PCR of a single 
transcript for HPRT performed in duplicate. 
The single peak represents one single specific amplicon. 
 
2.11. ELISA (enzyme-linked immunosorbent assay) and RIA 
(radioimmunoassay) 
 
2.11.1. Preparation of protein lysates 
Testis tissue samples were homogenized with PBS and protease inhibitor cocktail 
(Sigma, Steinheim, Germany or Calbiochem, MA, USA) using a Potter S tissue 
homogenizer or by using 5 mm stainless steel beads (Qiagen) and tissue lyser (Qiagen) 
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at 40 oscillations/second for at least 1 min. Insoluble components were removed by 
centrifugation of homogenized tissues at 14,000 x g for 10 min at 4°C.  
 
2.11.2. Measurement of protein concentration 
Total protein measurement was performed using the Pierce BCA Protein Assay 
(Thermo Scientific, Rockford, USA) following the manufacturer’s instructions. Briefly, 
samples were diluted 1:10 in distilled water. Different concentration of the provided BSA 
standard were prepared ranging between 0 and 2000 µg/ml. 25 µl of each standard and 
each unknown sample duplicate were pipetted into a 96 well microplate. 200 µl of the 
BCA working reagent (1 part of reagent B into 50 parts of reagent A) were added to 
each well. The plate was incubated at 37°C for 30 min. Finally, concentrations were 
assessed after measuring the optical density by the microplate ELISA reader (Berthold, 
Bad Wildbad, Germany and Labsystems, Vantaa, Finland) at either 570 nm (Giessen) 
or 492 nm (Monash). 
 
2.11.3. Activin A and B ELISA 
Activin A was measured using a specific two-site enzyme immunoassay as described 
previously (Knight et al., 1996, O'Connor et al., 1999, Okuma et al., 2006). The optical 
density was measured in a microplate ELISA reader (Labsystems) using dual 
wavelengths (450 nm and 630 nm). The concentration was calculated by Genesis 
software based on the measurement of optical density of the recombinant activin A 
standard and each sample. Sensitivity of the activin A ELISA ranged between 6.1 pg/ml 
and 1.98 ng/ml with an intra-assay coefficient of variability (CV) of 5.6% for the study I 
(samples from groups I, II and III). For the study II (samples from groups IV and V) 
sensitivity ranged between 12 pg/ml and 3.97 ng/ml with an intra and inter-assay CV of 
7%.  
 
Activin B protein levels were also evaluated using the enzyme linked immunosorbent 
assay (ELISA) as described previously (Ludlow et al., 2009). Briefly, plates were coated 
overnight with the 46A/F activin B antibody (3.9 mg/ml), then washed and blocked with 
1% BSA in PBS with 6% sucrose. Samples were denatured in 6% SDS by boiling for 3 
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min, and then added to the wells with human recombinant activin B used as a standard. 
Biotinylated 46A/F was used as detection antibody, followed by streptavidin-poly-HRP 
(horseradish peroxidase) and incubated for 1 hour, then the TMB (tetramethylbenzidine) 
substrate solution (Life Technologies, Frederick, USA) was added for 20 min. Finally, 
300 mM H2SO4 was added to stop the enzymatic reaction and absorbance at 450 nm 
was measured. Sensitivity of the activin B ELISA ranged between 8.1 pg/ml and 2.46 
ng/ml and intra-assay CV was 7.8%. 
 
2.11.4. Measurement of follistatin, inhibin and hormones (FSH, LH and 
testosterone) by RIA 
Concentrations of follistatin in mouse tissue homogenates and serum samples were 
measured using a heterologous, discontinuous radioimmunoassay (RIA), as described 
previously (O'Connor et al., 1999, Winnall et al., 2013). Assay sensitivity ranged 
between 1.33 ng/ml and 87.1 ng/ml and an intra assay CV of 9.8% for the study I 
samples from groups I, II and III. For study II samples from groups IV, V and VI, 
sensitivity ranged between 0.95 ng/ml and 199 ng/ml and the intra-assay CV was 
12.3%. 
 
Inhibin levels in mouse testicular homogenates were also measured by a heterologous 
RIA, as described previously (Robertson et al., 1988, Winnall et al., 2013). This assay 
detects total inhibin, e.g. all proteins containing the inhibin -subunit (inhibin A and B, as 
well as some free α-subunit peptides). The intra-assay CV was 6.4%, inter-assay CV 
was 5.9% and the sensitivity ranged between 58.76 ng/ml and 1.24 ng/ml for the 
samples from groups I, II and III (study I). For samples from groups IV, V and VI (study 
II), sensitivity ranged between 0.94 ng/ml and 315.42 ng/ml. 
 
FSH, LH and testosterone serum levels were also measured by RIA. FSH and LH 
assays were provided by the National Hormone and Peptide Program (Harbor-UCLA 
Medical Center, Dr. A.F. Parlow) and testosterone assay was done using a testosterone 
kit (Immunotech IM1119, Beckman Coulter, Prague, Czech Republic) provided by 
Beckman. The intra-assay CV of the FSH assay was 3.9% and sensitivity ranged 
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between 0.94 ng/ml and 28.70 ng/ml. The intra-assay CV of the LH assay was 7.7% 
and sensitivity ranged between 0.10 ng/ml and 14.7 ng/ml. The intra-assay CV of the 
testosterone assay was 9.5% and sensitivity ranged between 47.6 pg/ml and 46.6 
ng/ml. 
 
2.12. Isolation of mouse testicular cells 
Mouse testicular somatic cells (peritubular and Sertoli cells) were isolated to study the 
effects of cytokines on the inflammatory and fibrotic response by these cells. The 
isolation protocols were based on well-established protocols for isolating testicular cells 
from rodents (Bhushan et al., 2016, Okuma et al., 2005, Zeyse et al., 2000, O'Brien et 
al., 1989, Fillion et al., 1994), which were modified and optimized as described in the 
following sections. 
 
2.12.1. Isolation of peritubular cells 
Ten 21 day old C57BL/6J mice were killed by cervical dislocation. Testes were collected 
and kept in sterile DMEM/F12 medium. Under a laminar flow, testes were decapsulated 
and dissociated using 2 forceps. In order to isolate the seminiferous tubules, tissue was 
placed in a 50 ml falcon tube and digested with 5 ml collagenase solution (1 mg/ml) in a 
34°C shaking water bath (60 cycles/min) for 20 min, (Fig. 15a). Afterwards, 40 ml of 
DMEM/F12 medium was added in order to dilute the collagenase and tubules were left 
to settle at the bottom of the tube for 5 min. The supernatant was discarded carefully 
using a 5 ml serological pipette in order to eliminate the interstitial cells. Then tubules 
were washed twice with DMEM/F12 medium. In order to further dissociate the tubules 
and release the peritubular cells (PTC), a second digestion of the tubules in 5 ml trypsin 
(1 mg/ml) was performed for 20 min in a 34°C shaking water bath (60 cycles/min) (Fig. 
15b). 5 ml of soybean trypsin inhibitor solution (SBTI; 0.1 mg/ml) was added to the 
tubules to neutralize trypsin and the tubules were left to settle at the bottom of the tube 
for 5 min. The supernatant containing the PTC was carefully collected and transferred 
into a new Falcon tube (Fig. 15c). The remaining tubules were washed twice with 
DMEM/F12 medium, left to settle each time and the supernatant was collected and 
added to the tube containing the PTC. PTC were centrifuged at 400 x g for 10 min, 
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supernatant was discarded and pellet containing PTC was resuspended in 20 ml DMEM 
with 10% FCS and plated in one 75 cm2 flask. Cells were cultured for 48 hours at 37°C 
and 5% CO2. After 48 hours, attached PTC were washed twice with sterile PBS in order 
to remove contaminating interstitial and germ cells, and then left for approximately 48 
hours to become confluent. Afterwards, cells were transferred into two new 75 cm2 
flasks. PTC were grown until confluence of 90% was reached and then seeded into 
48-well plate for treatments and evaluation of purity by SMA and Sox9 staining (Fig. 
15d). 
 
Figure 15: Isolation of peritubular cells from immature mouse testes. 
Decapsulated testes from 21 day old C57BL/6J mice were digested using collagenase 
for 20 min causing seminiferous tubule dissociation (a). PTC were released in the 
supernatant following trypsin-DNase digestion for 20 min at 34°C (b). Trypsin activity 
was inhibited using SBTI. PTC culture after splitting and removal of contaminating cells 
(c). Sox9 (SC marker) and SMA double staining of PTC (green) after passaging 
showing very high  purity, and no contamination with SC, (d). Scale bars represent 100 
µm. 
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2.12.2. Isolation of Sertoli cells 
In order to purify the Sertoli cells, the remaining seminiferous tubules were digested 
further with 5 ml hyaluronidase solution (1 mg/ml) for 15 min in a shaking water bath 
(60 cycles/min) at 34°C, then the cells were dissociated by aspirating and releasing 
them for 4-5 times using a 5 ml serological pipet. DMEM/F12 was added to inhibit 
hyaluronidase activity and tubules were centrifuged at 400 x g for 3 min. Finally the 
supernatant was discarded and the pellet was resuspended in DMEM/F12 and filtered 
into a new tube through a 100 µm cell strainer to remove existing cell clumps. The 
solution containing cells was centrifuged at 400 x g for 3 min, the supernatant was 
discarded and SC were resuspended in 2 ml DMEM + 0.1% BSA. Cells were stained 
with trypan blue (Sigma, St Louis, USA) and counted using a Neubauer counting 
chamber, resuspended to a concentration of 1 x 106 cells/ml and 500 µl of cell 
suspension was seeded (500,000 cells/well) in a 48-well plate. The steps of the Sertoli 
cell isolation are shown in Figure 16. Cells were cultured for 48 hours at 37°C and 5% 
CO2. Subsequently, contaminating germ cells were treated by hypotonic shock and 
removed. Briefly, SC medium was removed, and 20 mM Tris-HCl solution was added to 
each well for 1.5 min. Afterwards SC were washed with PBS and cultured for 24 hours 
in DMEM + 0.1% BSA before following treatments. 
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Figure 16: Isolation of Sertoli cells from immature mouse testes. 
Seminiferous tubules after removal of peritubular cell formed very small tubular 
fragments (a). Fragments of seminiferous tubules were further digested for 15 min by 
hyaloronidase solution (b). A small aliquot of Sertoli cell suspension was stained by 
trypan blue and counted in a Neubauer counting chamber (c). Two days after seeding, 
contaminating germ cells were removed from the Sertoli cell culture by hypotonic shock 
treatment (d). Scale bars represent 100 µm. 
 
2.13. Effect of TNF and activin A on Sertoli and peritubular cells 
in vitro 
In order to directly investigate changes in the function and the regulation of fibrotic 
genes in Sertoli and peritubular cells during EAEO, an in vitro model mimicking aspects 
of the in vivo inflammatory milieu of the EAEO testis was established. Isolated Sertoli 
cells or peritubular cells were seeded in a 48-well plate at a concentration of 200,000 
cells per well. Cells were treated with recombinant mouse TNF (aa 80-235, R&D 
Systems, Minneapolis, USA) or recombinant human/mouse/rat activin A (338-AC/CF, 
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R&D Systems). Eight doses of TNF and activin A, ranging from 0 to 200 ng/ml were 
tested. Treatments were performed for 24 and 48 hours. Experiments were carried out 
on four independent cell isolations. Each treatment was performed in triplicate. After 24 
or 48 hours, media were collected and frozen at -20°C for activin A ELISA.  
 
2.14. Statistical analysis 
Data were expressed as means ± SEM from at least 3 independent experiments. 
Statistical analyses were performed using the unpaired t-test followed by Welch’s 
correction when 2 experimental groups were compared; one-way ANOVA followed by 
Tukey’s multiple comparisons or two-way ANOVA followed by Sidak’s multiple 
comparisons when more than 2 experimental groups were compared. Pearson’s 
correlation was used in order to show the linear relationship between two sets of data 
and how well they relate. Pearson’s correlation coefficient “r” is a measure of the 
strength of the association between the two variables. r=-1 represents a negative 
correlation, r=0 represents no correlation and r=+1 represents a positive correlation. 
P-values <0.05 were considered as a statistically significant difference. All tests were 
performed using GraphPad Prism 6 software (GraphPad Software, San Diego, USA). 
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3. RESULTS 
 
Study I 
Study I involved comparison of the induction of EAEO in C57BL/6N mice using TH with 
two different adjuvants, CFA and TiterMax Gold, and B. pertussis toxin injection. In this 
study, the efficiency of each adjuvant was evaluated in relation to the induction rate of 
EAEO. Moreover, the testes from mice that developed the disease were analyzed in 
terms of (a) inflammation as assessed by presence of immune cell infiltrates and 
expression of cytokines, (b) fibrosis, and (c) the expression profile of activins, follistatin, 
inhibin and activin receptors. 
 
3.1. Induction rate of EAEO in C57BL/6N mice 
A reduction in the weight of one or both testes was an indicator of EAEO development. 
The paired testis weights from mice in the different immunization groups and their 
respective controls are shown in Figure 17. The average testis weight 30 days after the 
first immunization was similar in all investigated mice from group I (Fig. 17). Animals 
from group I, immunized three times with TH in CFA, showed an approximately 2-fold 
reduction in testis weight at 50 (n = 7) and 80 (n = 5) days after the first immunization 
compared with untreated (n = 5) and adjuvant control (n = 5 for 50 days and n= 4 for 80 
days) groups (Fig. 17). Mice from group II, immunized three times with TH in TiterMax 
Gold adjuvant, showed a decrease in mean testis weight at 50 days (n = 8) after the first 
immunization compared with untreated (n = 5) controls, but no change was observed in 
the testis weight 80 days (n = 8) after the first immunization compared with both controls 
(n =5) (Fig. 17b). In contrast, mice from group III, immunized only twice with TH in 
Titermax Gold adjuvant (Fig. 17c), did not show any change in the testicular weight at 
all time points investigated. The macroscopic difference in testicular size of control and 
mice with severe EAEO, 50 days after the first immunization is shown in Fig. 17d. 
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Figure 17: Testicular weights and size of mice in study I. 
Paired testicular weights of untreated, adjuvant control and immunized (EAEO) mice 30, 
50 and 80 days after the first immunization from study I (a-c). Representative image 
showing macroscopic difference in testicular size from control mice and EAEO mice 50 
days after the first immunization (d). Data are expressed as mean ± SEM (n = 4 - 8 
animals per group; numbers of animals per group are shown in the respective columns). 
Statistical analysis was performed using one-way ANOVA followed by Tukey’s multiple 
comparison test; *P<0.05 and ****P<0.0001, all other comparisons were not statistically 
significant.  
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The induction rate of EAEO was calculated based on testicular weight and 
histopathological changes in the testicular architecture (Table 4) (described in detail in 
section 3.2). All immunized mice from group I developed EAEO at 50 and 80 days after 
the first immunization (7/7 and 5/5 mice, respectively), whereas 30 days after the first 
immunization, only 33% (2/6) mice showed histological signs of the disease. 
Animals from groups II and III showed a significantly lower induction rate of EAEO. 50% 
of the mice from group II developed the disease (4/8 mice) and only 12.5% from group 
III (1/8 mice) at 50 days and from group II at 80 days, respectively as shown in Table 4b 
and c. Therefore the mice from groups II and III were not considered for further 
investigations and all subsequent data shown from study I is only from mice of group I. 
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Table 4: Induction rate of EAEO in treatment groups from study I.  
 
Group I: three immunizations with CFA, group II: three immunizations with TiterMax 
Gold, group II: two immunizations with TiterMax Gold. 
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3.2. Morphological changes in EAEO testes 
The grade of EAEO development was variable between individual mice from group I, 
therefore TH-immunized mice that developed EAEO were subdivided into mice with 
severe disease symptoms (severe EAEO) and mice showing only mild symptoms of 
EAEO (low grade EAEO). Histopathological changes and the fibrotic response were 
assessed by azo-carmine and aniline blue staining (azan), as shown in Figure 18. 
 
3.2.1. Altered histology in EAEO testes 
The changes in inflamed testes included reduced diameter of the seminiferous tubules, 
germ cell sloughing leading to Sertoli cell only tubules and leukocytic infiltrates in the 
interstitium (Fig. 18).  
Testes from the severe EAEO group at 50 (Fig. 18h) and 80 (Fig. 18l) days after the 
first immunization, displayed a complete destruction of testicular morphology with a 
reduction of the diameter of the seminiferous epithelium, tubular atrophy and thickening 
of the seminiferous lamina propria. An increase of the immune cell infiltrates in EAEO 
testes was also observed (as described in section 3.3.2). In contrast, in the mild form of 
the disease, some of the seminiferous tubules were still intact. Moreover, testes from 
untreated (Fig. 18a, e, i) and adjuvant control mice (Fig. 18b, f, j) showed a normal 
morphology with seminiferous tubules containing Sertoli cells as well as germ cells at all 
stages of spermatogenesis. In accord, morphological changes were also observed in 
human testicular biopsies with impaired spermatogenesis and inflammatory infiltrates 
(Fig. 19b). 
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Figure 18: Morphological changes and fibrotic response in EAEO testes. 
Azo-carmin and aniline blue staining of collagen fibers in paraffin sections from 
untreated (a, e, i), adjuvant control (b, f, j), low grade (c, g, k) and severe EAEO (d, h, 
l) mouse testes at 30 (a - d), 50 (e - h) and 80 (i - l) days after the first immunization. An 
increase in collagen fibers was visible in low grade EAEO in the areas with lymphocytic 
infiltrates. A strong peritubular fibrotic response was detectable in EAEO mouse testes 
at 50 (h) and 80 (l) days after the first immunization. Scale bars represent 100 µm. 
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Figure 19: Morphological differences between human testes with intact 
spermatogenesis and inflamed testes with impaired spermatogenesis. 
Hematoxylin and eosin staining (a, b), azo-carmine and aniline blue staining of collagen 
fibers (c, d) and immunofluorescence distribution of SMA (e, f) in testicular biopsies 
from infertile men showing seminiferous tubules with intact spermatogenesis and 
absence of any signs of inflammation in the interstitial compartment (a, c, d) and human 
testis specimens with impaired spermatogenesis and infiltration by non-resident immune 
cells (b, d, f). An increase in collagen fibers reflecting severe alteration of the lamina 
propria (thickening, “meshwork” pattern), tubular atrophy and expanded vascularization 
was visible in the testes with impaired spermatogenesis (d) close to the areas with 
lymphocytic infiltrates (asterisks) (b), accompanied by a thicker distribution of the SMA 
layer which was spread within the cells (f). SMA was also seen in the blood vessels 
(arrows) within the interstitium. In testes with normal spermatogenesis, there was no 
detectable fibrotic response (c) and SMA is localized in the peritubular cells as a thin 
layer (e). Scale bars represent 100 µm. 
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3.2.2. Strong fibrotic responses in EAEO testes 
The morphological changes in EAEO were accompanied by a strong fibrotic response in 
the testes represented by an increase of the collagen fibers around the remaining empty 
tubules, and thickening of the lamina propria, especially at 50 (Fig. 18h) and 80 (Fig. 
18l) days after the first immunization. Similar changes were also observed in human 
testicular biopsies with impaired spermatogenesis and inflammatory infiltrates (Fig. 
19d).  
 
3.2.2.1. Altered distribution of -smooth muscle actin (SMA) in EAEO 
testes  
In order to investigate further the peritubular fibrotic response observed in EAEO testes, 
an analysis of -smooth muscle actin (SMA) localization and distribution by 
immunofluorescence staining was performed (Fig. 20). The staining revealed a change 
in the distribution of the SMA layer in low grade EAEO at 30, 50 and 80 days (Fig. 
20c, g, k, o) in areas where the seminiferous tubules were smaller and 
spermatogenesis was disrupted. The altered distribution and thickening of the SMA 
layer was more pronounced in severe EAEO at 30, 50 and 80 days (Fig. 20d, h, l, p). 
The layer of SMA was diffusely distributed within the peritubular cells in EAEO testes 
compared to a thin and compact layer in untreated and adjuvant control testes. The 
same altered distribution of the layer of SMA was also observed in human testis 
samples with focal inflammatory lesions and impaired spermatogenesis (Fig. 19f). 
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Figure 20: Distribution of -smooth muscle actin (SMA) was altered in EAEO 
testes. 
Distribution of -smooth muscle actin (SMA) in paraffin sections from untreated (a, e, i, 
m), adjuvant control (b, f, j, n), low grade (c, g, k, o) and severe EAEO (d, h, l, p) 
testes at 30 (a - d), 50 (e - h) and 80 (i - l) days after the first immunization. Panels m - 
p represent a higher magnification of images i - l. In the testes from untreated and 
adjuvant controls, SMA was localized in the peritubular cells as a thin layer, but in low 
grade and severe EAEO testes, the SMA was diffusely distributed within the cell. 
SMA was also seen in the blood vessels (asterisks) within the testes. Scale bars 
represent 100 µm. 
 
3.2.2.2. Increased numbers of mast cells in EAEO testes 
Since mast cells are involved in promoting fibrotic response in several diseases by 
releasing tryptase from their granules (Wilgus and Wulff, 2014), staining of testicular 
mast cells was performed as shown in Figure 21. The staining revealed that, although 
scarce, mast cells were present in testes under normal conditions (Fig. 21a-b). The 
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mast cells were found either within the blood vessels of the testis or in close proximity to 
the tunica albuginea. In low grade EAEO (Fig. 21c), mast cells seemed more prevalent 
in the areas of leukocytic accumulation and around smaller tubules showing a 
thickening of the lamina propria as shown in Figure 18c, whereas in severe EAEO, 
mast cells seemed more evenly distributed within the testes and the increase in their 
number was visibly evident, although not counted. 
 
Figure 21: Mast cell numbers were increased in EAEO testes. 
Toluidine blue staining of mast cells in testicular paraffin sections from untreated (a), 
adjuvant control (b), low grade (c) and severe EAEO (d) testes. Arrows point to mast 
cells. Under normal conditions, mast cells were present in very low numbers in the 
interstitial space (a-b). An accumulation of mast cells was observed in low grade EAEO 
testes (c) around areas with immune cell infiltrates and smaller seminiferous tubules. An 
evident increase in the number of mast cells was seen in severe EAEO testes (d). Scale 
bars represent 50 µm. 
 
 
 
 
 Results 
 
- 62 - 
 
3.3. Inflammatory responses in EAEO testes  
In order to investigate the inflammatory response in the EAEO and control testes, an 
analysis of the mRNA expression of inflammatory mediators and presence of different 
immune cell populations was performed. 
 
3.3.1. Expression of inflammatory mediators was increased in EAEO testes 
Relative mRNA expression of inflammatory mediators (TNF, IL-6, IL-10 and MCP-1) 
was quantified using quantitative RT-PCR in order to evaluate if immunized mice 
developed testicular inflammation.  
At 30 days after the first immunization, the mRNA expression levels of TNF, MCP-1 
(encoded by the Ccl2 gene), IL-10 and IL-6 in EAEO testes were unchanged in EAEO 
testes and controls (Fig. 22). Further analysis showed a 20-fold increase of TNF(Fig. 
22a) and MCP-1 (Fig. 22b), as well as an approximately 10-fold upregulation of IL-10 
(Fig. 22c) mRNA expression in EAEO testes 50 days after the first immunization 
compared to untreated and adjuvant control testes. At 80 days after the first 
immunization, an increase of TNF (Fig. 22a), MCP-1 (Fig. 22b) and IL-10 (Fig. 22c) 
mRNA levels was also observed in EAEO testes, by comparison with untreated control 
groups and both untreated and adjuvant controls for MCP-1 (Fig. 22b). Notably, the 
IL-10 mRNA level was slightly increased in adjuvant control testes, by comparison with 
untreated control group 50 days after the first immunization (Fig. 22c). IL-6 mRNA 
levels in EAEO were comparable to both controls at all time points investigated (Fig. 
22d). 
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Figure 22: Expression of inflammatory mediators was elevated in EAEO testes. 
Tnf (a), Ccl2 (MCP-1) (b), Il10 (c) and Il6 (d) mRNA expression was measured in 
untreated, adjuvant control and EAEO mouse testes at 30, 50 and 80 days after the first 
immunization. Relative mRNA levels were analyzed using quantitative RT-PCR. Data 
are represented as mean ± SEM (n = 4 - 5 animals per group). Statistical analysis was 
done using one-way ANOVA followed by Tukey’s multiple comparisons; *P<0.05, 
**P<0.01, ***P<0.001, ****P<0.0001, all other comparisons were not statistically 
significant. 
 
3.3.2. Immune cell populations were increased in EAEO testes 
In addition to the increased numbers of mast cells (as presented in section 3.2.2.2), the 
presence of different immune cell populations in testes under normal or inflammatory 
conditions was evaluated either by immunofluorescence staining or  flow cytometry. 
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3.3.2.1. Testicular macrophages were increased in EAEO testes 
Although not quantified, immunofluorescence analysis data suggested that the number 
of F4/80 and CD206 positive macrophages were considerably more prominent in EAEO 
testes (Fig. 23). In untreated mouse testes, few macrophages were found in the 
interstitial space (Fig. 23c). Notably, the majority of these cells were F4/80 and 
CD206-positive indicating an M2 anti-inflammatory phenotype (Fig. 23a). A similar 
distribution of the testicular macrophages was also observed in adjuvant control testes 
(Fig. 23f). However, adjuvant treatment alone led to a slight increase in the number of 
macrophages by comparison with untreated controls. In contrast, in low grade EAEO 
testes, an accumulation of co-localized F4/80 and CD206-positive cells with increased 
numbers of F4/80-positive/CD206-negative cells (Fig. 23i) was observed, mainly in the 
areas where the diameter of the seminiferous tubules was reduced. This accumulation 
was evident in severe EAEO (Fig. 23l) at 50 days after the first immunization, 
suggesting that the infiltrating macrophages possess a pro-inflammatory M1 phenotype. 
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Figure 23: Increased numbers of pro-inflammatory M1 macrophages in EAEO 
testes. 
Double staining for CD206 (AlexaFluor546, orange) (a, d, g, j) and the macrophage 
marker F4/80 (AlexaFluor488, green) (b, e, h, k) in testicular cryosections from 
untreated (a - c), adjuvant control (d - f), low grade EAEO (g - i) and severe EAEO (j - l) 
mice. Nuclei were counterstained with DAPI (blue). Under non-inflammatory conditions, 
co-localized CD206 and F4/80-positive macrophages were present in low numbers in 
the interstitial space (c, f). An accumulation of double positive F4/80 and CD206 
macrophages was observed in adjuvant controls (f), inflamed low grade (i) and severe 
50 day EAEO testes (l), with a higher number of F4/80 positive only (CD206-negative) 
cells. In low grade 50 day EAEO testes (i), the accumulation of macrophages was 
present in areas with reduced tubule diameter, whereas in severe 50 day EAEO testes 
(l) macrophages were more evenly distributed in the interstitial space. Scale bars 
represent 100 µm. 
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3.3.2.2. CD45+ leukocytes and CD3+ T cells numbers were increased 
in EAEO testes 
After gating out debris, doublets, and nonviable cells, flow cytometric analysis revealed 
an increased percentage of leukocytes (CD45+) in EAEO testes (Fig. 24a and b). 
Depending on the stage of the disease, the highest increase in the number of CD45+ 
cells was observed in severe EAEO testes, showing in some animals that nearly 50% of 
testicular cells were CD45+ leukocytes. Within the population of leukocytes, an increase 
of CD3+ T cell numbers was observed (Fig. 24c). Further analysis of different T cell 
subtypes within the gated CD3+ T cell population revealed an increase in the population 
of CD4+CD8- and activated CD4+CD25+ T cells in inflamed testes, while the 
percentage of CD4-CD8+ T cells was decreased, by comparison with untreated and 
adjuvant control testes. Interestingly, a new subpopulation of double positive 
CD4+CD8+ T cells within testicular CD3+ T cell population was identified in EAEO 
testes (Fig. 24d). Moreover, the CD4+/CD8+ T cell ratio showed an approximately 
5-fold increase in EAEO testes, by comparison with untreated and adjuvant control 
testes (Fig. 24e). 
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Figure 24: T cells (CD3+) and their different subtypes (CD4-CD8+, CD4+CD8+, 
CD4+CD8- and CD4+CD25+) were increased in EAEO testes. 
Representative flow cytometry plots for testicular CD45+ leukocytes (a) evaluated in the 
testicular single cell suspension. Percentage of CD45+ leukocytes (a, b), CD3+ T cells 
within CD45+ leukocytes (c) and different subtypes of CD3+ T cells such as CD4-CD8+, 
CD4+CD8+, CD4+CD8- and CD4+CD25+ T cells (d) was analyzed in untreated, 
adjuvant control and EAEO testicular single cell suspension 50 days after the first 
immunization, by flow cytometry. The ratio between CD4+ / CD8+ T cells in testes from 
untreated, adjuvant control and EAEO mouse was calculated using flow cytometric 
analysis (e). After gating out cell debris, doublets and nonviable cells, the population of 
CD45+ leukocytes and CD3+ T cells was selected for further analysis. Data are 
expressed as mean ± SEM (n = 5 animals per group); *P<0.05, **P<0.01, ***P<0.001, 
all other comparisons were not statistically significant. (Courtesy of Dr. Monika Fijak). 
 
3.4. Peritubular cells did not proliferate in EAEO testes 
PCNA staining for detecting cell proliferative ability in testes was performed in order to 
evaluate if the morphological change in the distribution of the SMA layer was due to a 
potential for proliferation of peritubular cells. PCNA staining showed that in untreated 
(Fig. 25a) and adjuvant control (Fig. 25b) testes, spermatogonia and spermatocytes in 
the seminiferous tubules were proliferating. This proliferation was gradually lost in low 
grade EAEO in the areas where the seminiferous epithelium was affected (Fig. 25c). In 
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severe EAEO, only a small number of cells within the seminiferous epithelium showed 
evidence of proliferation but not peritubular cells. Interestingly, some cells in the 
interstitial space in EAEO testes showed proliferative activity.  
 
Figure 25: Proliferation of testicular cells was altered in EAEO testes. 
PCNA staining of paraffin-embedded testicular sections from untreated (a), adjuvant 
control (b), low grade EAEO (c) and severe EAEO (d) mice 50 days after the first 
immunization. Under normal conditions, spermatogonia and spermatocytes were PCNA 
positive (a, b). During inflammation, a very small number of germ cells was PCNA 
positive particularly in seminiferous tubules with smaller diameter in closer proximity to 
leukocytic infiltrates and also some cells in the interstitial space were PCNA positive (c, 
d). Insets are negative controls lacking primary antibody. Scale bars represent 100 µm. 
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3.5. Expression of activin, inhibin and follistatin was altered in 
EAEO testes 
 
3.5.1. Localization of activin A in normal and inflamed mouse testes 
Activin A immunofluorescence staining (Fig. 26) revealed that the A subunit was 
localized mainly in the cytoplasm of Sertoli cells, as well as in some interstitial cells in 
untreated and adjuvant control testes at 30 (Fig. 26a, b), 50 (Fig. 26e, f) and 80 (Fig. 
26i, j) days. A similar pattern of activin A expression was also observed in low grade 
EAEO at 30 (Fig. 26c), 50 (Fig. 26g) and 80 (Fig. 26k) days. In contrast, in severe 
EAEO testes at 30 (Fig. 26d), 50 (Fig. 26h) and 80 (Fig. 26l) days after the first 
immunization, strong activin A staining was detectable in cells within the inflammatory 
infiltrates and in Sertoli cells.  
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Figure 26: Localization of activin A subunit in EAEO testes was different from 
normal testes. 
Immunofluorescence staining of activin A subunit using the E4 antibody on paraffin 
sections from untreated (a, e, i), adjuvant control (b, f, j), low grade (c, g, k) and severe 
EAEO (d, h, l) testes at 30 (a - d), 50 (e - h) and 80 (i - l) days after the first 
immunization. The activin A subunit was localized in the cytoplasm of Sertoli cells 
(arrowheads), peritubular cells and some interstitial cells (arrows) in untreated, adjuvant 
controls and low grade EAEO. In severe EAEO testes, the staining was present in 
Sertoli cells and individual immune cells (d, h, l). Scale bars represent 100 µm. 
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3.5.2. Activin A and B but not inhibin expression was changed in EAEO 
testes  
Activin A (Fig. 27a), activin B (Fig. 27b) and inhibin (Fig. 27c) protein levels in EAEO 
testes were similar to untreated and adjuvant control testes at 30 days after the first 
immunization. In contrast, in 50 days EAEO testes, protein levels of activin A and B 
showed an approximately 4-fold and 2-fold increase, respectively, by comparison with 
untreated and adjuvant control mice, whereas inhibin levels in EAEO testes did not 
show significant change compared to both controls. In the chronic phase of the disease 
at 80 days, no significant change in the testicular concentrations of activin A and B or 
inhibin was detected, although a slight increase in protein levels of activin A and B was 
observed by comparison with controls (Fig. 27). 
 
Figure 27: Elevated protein levels of activins A and B and inhibin in EAEO testes. 
Protein levels of activin A (a), activin B (b) and inhibin (c) were measured in testicular 
homogenates from untreated, adjuvant control and EAEO animals 30, 50 and 80 days 
after the first immunization. Data are represented as mean ± SEM of 4 - 5 animals per 
group. Statistical analysis was done using one-way ANOVA followed by Tukey’s 
multiple comparisons; *P<0.05, **P<0.01, all other comparisons were not statistically 
significant. 
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Interestingly, gene expression analysis showed no significant change in activin A 
(Inhba) mRNA levels in testes of all mice at any time point (Fig. 28a). The mRNA levels 
of activin B (Inhbb) (Fig. 28b) and inhibin α (Inha) (Fig. 28c) subunits were unchanged 
in EAEO testes, untreated and adjuvant controls at 30 and 50 days after the first 
immunization, however, their expression decreased in 80 days EAEO testes compared 
to adjuvant control testes (Fig.28b and c).  
 
Figure 28: Decreased mRNA expression of inhibin subunits Inhbb (inhibin B) 
and Inha (inhibin ) in 80 day EAEO testes. 
Relative mRNA expression of Inhba (inhibin A) (a), Inhbb (inhibin B) (b), Inha (inhibin 
) (c) in testes from untreated, adjuvant control and EAEO mice 30, 50 and 80 days 
after the first immunization, analyzed by quantitative RT-PCR. Data are represented as 
mean ± SEM of 4 - 5 animals per group. Statistical analysis was done using one-way 
ANOVA followed by Tukey’s multiple comparisons; *P<0.05, **P<0.01, ***P<0.001, all 
other comparisons were not statistically significant. 
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3.5.3. Activin A receptor expression was decreased in EAEO testes 
In order to elucidate the influence of testicular inflammatory processes on activin A 
signaling, mRNA expression of activin receptors was analyzed. Interestingly, activin A 
receptor type IB (Acvr1b) mRNA expression was decreased in 50 and 80 days, but not 
in 30 day EAEO testes, by comparison with untreated and adjuvant control testes (Fig. 
29a). Similarly, activin receptor type IIB (Acvr2b) mRNA levels were decreased in 50 
days EAEO testes, by comparison with untreated control testes (Fig. 29b). No 
significant difference in the Acvr2b mRNA expression levels was detected in testes from 
30 and 80 days EAEO animals, by comparison with control testes (Fig. 29b). 
 
Figure 29: Decreased mRNA expression of activin A receptors in EAEO testes. 
Relative mRNA expression of Acvr1b (activin receptor, type IB) (a) and Acvr2b (activin 
receptor, type IIB) (b) in testes from untreated, adjuvant control and EAEO mice 30, 50 
and 80 days after the first immunization, analyzed by quantitative RT-PCR. Data are 
represented as mean ± SEM of 4 - 5 animals per group. Statistical analysis was done 
using one-way ANOVA followed by Tukey’s multiple comparisons; *P<0.05, **P<0.01, 
***P<0.001, all other comparisons were not statistically significant. 
 
3.5.4. Follistatin expression was upregulated in EAEO mouse testes  
Protein levels of follistatin (Fig. 30a) were unchanged in testes of all mice investigated 
at 30 days after the first immunization. In contrast, elevated testicular concentration of 
follistatin was measured in EAEO at 50 and 80 days after the first immunization by 
comparison with both controls (Fig. 30a). 
The mRNA levels of total follistatin Fst (Fig. 30b), tissue bound Fst288 (Fig. 30c) and 
circulating Fst315 form of follistatin (Fig. 30d) were not significantly changed at any time 
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points. However, mRNA levels of Fst showed a slight increase in expression in EAEO 
testis at 50 days and 80 days after the first immunization by comparison with both 
controls (Fig. 30b). 
 
Figure 30: Elevated levels of follistatin in EAEO testes. 
Protein levels of follistatin (a) and relative mRNA expression of Fst (b), Fst288 (c), and 
Fst315 (d) were measured in testicular homogenates from untreated, adjuvant control 
and EAEO mice testes 30, 50 and 80 days after the first immunization and relative 
mRNA expression was analyzed by quantitative RT-PCR. Data are represented as 
mean ± SEM of 4 - 5 animals per group. Statistical analysis was done using one-way 
ANOVA followed by Tukey’s multiple comparisons; *P<0.05, all other comparisons were 
not statistically significant. 
 
 
 
 
 
 Results 
 
- 75 - 
 
Study II 
 
The aim of this study was to evaluate the potential therapeutic role of exogenous 
follistatin for treatment of testicular inflammation. Circulating follistatin levels were 
elevated in C57BL/6J mice by an injection of recombinant adenovirus-associated viral 
vector containing the gene cassette of the circulating FST315 form of follistatin, 30 days 
before induction of EAEO. EAEO was induced using a modified immunization protocol 
with CFA + TH or CFA + NaCl for the first immunization and IFA + TH or IFA + NaCl for 
the following two booster immunizations. The immunization protocol in Study II was 
modified according to the Monash University Animal Ethics committee requirements 
regarding the use of the adjuvants. All immunizations were followed by an i.p. injection 
of Bordetella pertussis toxin. The induction rate of EAEO, histopathological changes, 
inflammatory and fibrotic responses as well as follistatin, activin and hormonal systemic 
and testicular levels were analyzed at 30 and 50 days after the first immunization. 
 
3.6. Serum levels of follistatin were elevated after FST315 
vector injection 
Follistatin and activin A serum levels were measured 30 days after the injection of the 
FST315 vector and the empty vector as a control (one day before the first 
immunization). Follistatin serum levels were 5-fold elevated in mice that received the 
FST315 vector (FST) compared to control mice injected with an empty vector (EV) (Fig. 
31a) alone. Activin A serum levels were not different between FST and EV mice (Fig. 
31b). 
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Figure 31: Elevated follistatin serum levels in mice 30 days after injection of the 
FST315 vector (one day before induction of EAEO). 
Protein levels of follistatin (a) and activin A (b) were measured in serum from mice 30 
days after the i.m. injection with empty (EV) or FST315 (FST) vector and exactly one 
day before the start of the induction of EAEO. Data are represented as mean ± SEM of 
12- 26 animals per group; numbers of animals per group are shown in the respective 
columns. Statistical analysis was done using unpaired T-test with Welch’s correction; 
****P<0.0001, all other comparisons were not statistically significant. Representative 
image of a male mouse injected with a follistatin vector in its tibialis anterior muscle 
developing a muscle hypertrophy 30 days after the vector injection (c). 
 
 
In order to verify whether follistatin levels were elevated at the final time points of the 
experiment, i.e. at 30 days and 50 days after the first immunization, follistatin levels 
were measured in serum of all mice. At 30 days after the first immunization (Fig. 32a), 
follistatin levels were 5-fold elevated in mice that received the FST315 vector and 3-fold 
elevated at 50 days after the first immunization compared to control mice injected with 
an empty vector (EV) alone (Fig. 32b). 
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Figure 32: Elevated follistatin serum levels in mice 30 and 50 days after the first 
immunization. 
Follistatin protein levels were measured in serum from untreated, adjuvant control and 
TH-immunized mice (EAEO) injected with empty (EV) or FST315 (FST) vector 60 and 
80 days after the vector injections (30 [a] and 50 [b] days after the first immunization, 
respectively). Data are represented as mean ± SEM of 3 - 6 animals per group. 
Statistical analysis was done using one-way ANOVA followed by Tukey’s multiple 
comparisons for all treatment groups and two-way ANOVA comparing EV and FST 
groups followed by Sidak’s multiple comparisons; ***P<0.001, ****P<0.0001; all other 
comparisons were not statistically significant. 
 
3.7. Induction rate of EAEO 
Similar to mice from group I (study I) that received three immunizations with TH in CFA, 
mice from group IV in study II injected with an empty vector showed a 2-fold reduction in 
the mean testis weight at 50 days (n = 4) after the first immunization, by comparison 
with untreated (n = 4) and adjuvant (n = 4) controls (Fig. 33a). Mice from group IV and 
V were immunized by using a modified immunization procedure, namely TH in CFA for 
the first immunization and TH with IFA for the following booster immunizations. Mice 
from group V treated with the FST315 vector (Fig. 33b) didn’t show any change in the 
mean testis weight in all investigated experimental groups. 
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Figure 33: Testicular weights of mice in study II. 
Paired testicular weight of untreated, adjuvant control and TH-immunized (EAEO) mice 
with normal (empty vector injection) (a) and elevated levels (FST315 vector injection) 
(b) of follistatin, 30 and 50 days after the first immunization (a - b). Data are expressed 
as mean ± SEM (exact numbers of animals per group are shown in the respective 
columns). Statistical analysis was done using one-way ANOVA followed by Tukey’s 
multiple comparisons; *P<0.05, **P<0.01, all other comparisons were not statistically 
significant. 
 
Successful induction of EAEO (Table 5) was determined based on parameters including 
reduced testis weight, histopathological changes in the testicular architecture (this 
aspect will be described in paragraph 3.8) and expression of pro-inflammatory 
mediators. 
40% (2/5) of mice from group IV injected with an empty vector before the induction of 
EAEO developed the disease 30 days after the first immunization compared to 75% 
(3/4) of mice that developed the disease at 50 days. In group V (FST315 vector 
injected), 40% (2/5) of mice developed the disease at 30 days and 50 days after the first 
immunization.  
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Table 5: Induction rate of EAEO in mice from study II.  
 
Group IV: mice injected with a recombinant adenovirus-associated viral vector carrying 
an empty gene cassette and immunized with CFA for the first immunization and IFA for 
the two following immunizations, group V: mice injected with a recombinant adenovirus-
associated viral vector carrying a gene cassette of the circulating FST315 form of 
follistatin and immunized with CFA for the first immunization and IFA for the two 
following immunizations. 
 
3.8. Morphological changes in EAEO testes of mice with normal 
and elevated levels of follistatin 
Histopathological changes in the testes of immunized mice from study II were assessed 
by PAS staining as represented in Figure 34. Moreover, the fibrotic response in the 
testes of investigated animals was assessed by Masson’s trichrome staining as shown 
in Figure 35 and by quantitative RT-PCR of fibrotic marker mRNA expression as shown 
in Figure 36. 
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3.8.1. Scoring of testicular damage in mice injected with an empty vector 
or the FST315 vector 
PAS staining was performed in order to assess the histopathological changes observed 
in testes of mice from study II (Figure 34). Testes from immunized mice showed a 
variable grade of EAEO development between individual mice. Overall, a milder form of 
the disease was observed by comparison with the mice developing EAEO from study I, 
where CFA was used for all three immunizations. Therefore, a scoring system of the 
disease progression was established as follows:  
 score 0 - normal testicular histology (Fig. 34a),  
 score 1 - normal testicular histology, but elevated levels of inflammatory 
mediators (TNF, IL-6, IL-10 and MCP-1) in the testis evaluated by quantitative 
RT-PCR as described in section 3.9 (Fig. 34b),  
 score 2 - focal leukocytic infiltrates accompanied by reduced diameter of the 
seminiferous tubules representing altered spermatogenesis (some seminiferous 
tubules has normal spermatogenesis) (Fig. 34c), 
 score 3 - sloughing of germ cells, numerous leukocytic infiltrates within the 
interstitial space, but also within some seminiferous tubules (Fig. 34d), 
 score 4 - significantly smaller testis weight showing a very damaged testicular 
histology, numerous leukocytic infiltrates, disrupted spermatogenesis and the 
majority of seminiferous tubules with reduced diameter (Fig. 34e), 
 score 5 - significantly smaller testis weight representing a complete destruction of 
the testicular morphology, loss of germ cells and overall infiltration of the testis by 
immune cells (Fig. 34f).  
All untreated and adjuvant control animals showed completely normal testicular 
morphology and spermatogenesis. 
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Figure 34: Score of EAEO development in mice from study II. 
PAS staining of testicular paraffin sections from immunized mice. Score 0 (a), score 
1 (b), score 2 (c), score 3 (d), score 4 (e), score 5 (f). Scale bars represent 100 µm. 
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3.8.2. Fibrotic responses in EAEO testes of mice with normal and elevated 
levels of follistatin 
Masson’s trichrome staining on testicular sections, from both TH-immunized mice with 
normal levels of follistatin and of those with elevated levels of follistatin, revealed an 
increase in collagen fibers in the areas with leukocytic accumulation and smaller 
seminiferous tubules with impaired spermatogenesis (score 2; Fig. 35c). The fibrotic 
response was stronger in testes of TH-immunized mice during the progression of the 
disease as classified by score 3 and 4 (Fig. 35d and e, respectively) by comparison 
with untreated and adjuvant controls and testes of TH-immunized mice with scores of 0 
to 2. An evident increase in the collagen deposits was observed at score 5 in EAEO 
testes, where the morphology was destroyed (Fig 35f), by comparison with untreated 
and adjuvant controls and testes of TH-immunized mice with scores of 0 to 2. 
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Figure 35: Fibrotic responses in EAEO testes of mice with either normal or 
elevated levels of follistatin. 
The fibrotic response was evaluated by Masson’s trichrome staining on testicular 
paraffin sections from TH-immunized mice (EAEO). The blue color represents the 
collagen fibers. Score 0 (a), score 1(b), score 2 (c), score 3 (d), score 4 (e), score 5 (f). 
Scale bars represent 100 µm. 
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Moreover, the fibrotic response was further evaluated by quantification of Col1a1 
(collagen type I, alpha 1) and Acta2 (SMA) mRNA expression in mice from both 
treatment groups (Figure 36) as both collagen type I, alpha 1 and SMA are considered 
as fibrotic markers. Although no difference in the expression levels of these two markers 
was recorded between TH-immunized mice (EAEO group) and their respective 
untreated and adjuvant controls, it is important to mention that one of the TH-immunized 
mice from the EV group which developed EAEO at a score of 5 (Fig. 36a and b) had 
elevated expression of Col1a1 by comparison with untreated and adjuvant controls, 
which was consistent with the histologically observed increase of collagen in its testis. 
 
Figure 36: Expression of fibrotic markers in testes of mice with either normal or 
elevated levels of follistatin. 
Relative mRNA expression of Col1a1 (collagen type I alpha 1) (a, b) and Acta2 (alpha 
smooth muscle actin) (c, d) in testes from untreated, adjuvant control and TH-
immunized mice (EAEO) injected with empty (EV) or FST315 (FST) vector 30 (a, c) and 
50 (b, d) days after the first immunization, analyzed by quantitative RT-PCR. Data are 
represented as a mean ± SEM of 3 - 5 animals per group. Statistical analysis was done 
using one-way ANOVA followed by Tukey’s multiple comparisons for all treatment 
groups and two-way ANOVA comparing EV and FST groups followed by Sidak’s 
multiple comparisons. 
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3.9. Expression of inflammatory mediators was increased in 
EAEO testes of mice with normal and elevated levels of 
follistatin 
As for study I, expression levels of inflammatory mediators in testes of TH-immunized 
mice from study II and their untreated and adjuvant controls were quantified using 
quantitative RT-PCR in order to assess whether elevated circulating follistatin had an 
effect on development of testicular inflammation. 
At 30 days after the first immunization, the mRNA expression levels of TNF (Fig. 37a), 
MCP-1 (Fig. 37c), IL-10 (Fig. 37e) and IL-6 (Fig. 37g) in TH-immunized groups were 
unchanged in all animals. At 50 days after the first immunization, mRNA levels of TNF 
(Fig. 37b) and MCP-1 (Fig. 37d) were significantly higher in testes of TH-immunized 
mice from the EV group by comparison with untreated controls, as well as by 
comparison with adjuvant controls for TNF (Fig. 37b). This elevation of the levels of 
TNF and MCP-1 was also seen in testes of TH-immunized mice treated with FST315 
vector (FST EAEO group) compared with their untreated and adjuvant controls, 
although it was not significant. In contrast, IL-6 mRNA expression was significantly 
higher in testes of TH-immunized mice from the FST group compared with adjuvant 
controls (Fig. 37h).  
 
 Results 
 
- 86 - 
 
 
Figure 37: Expression of inflammatory mediators was elevated in EAEO testes of 
mice with either normal or elevated levels of follistatin. 
Relative mRNA expression of Tnf (a-b), Ccl2 (MCP-1) (c-d), Il10 (e-f) and Il6 (g-h) was 
measured in testes from untreated, adjuvant control and TH-immunized mice (EAEO) 
injected with empty (EV) or FST315 (FST) vector 30 (a, c, e, g) and 50 (b, d, f, h) days 
after first immunization, analyzed by quantitative RT-PCR. Data are represented as 
mean ± SEM (n = 3 - 5 animals per group). Statistical analysis was done using one-way 
ANOVA followed by Tukey’s multiple comparisons for all treatment groups and two-way 
ANOVA comparing EV and FST groups followed by Sidak’s multiple comparisons; 
*P<0.05, all other comparisons were not statistically significant. 
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3.10. Apoptotic cells were increased in EAEO testes of mice with 
normal and elevated levels of follistatin 
Although not quantified, TUNEL staining revealed that under normal conditions, in 
untreated (Fig. 38a) and adjuvant (Fig. 38b) control testes a few apoptotic cells were 
present within the seminiferous epithelium. Similar amount of apoptotic cells was 
detected in testes of TH-immunized mice from both groups IV and V, which didn’t 
develop any histological signs of EAEO, namely score 0 (Fig. 38c) and score 1 (Fig. 
38d). An evident increase in the amount of apoptotic cells was visible starting from 
score 2 (Fig. 38e), particularly inside the smaller tubules. This increase was even more 
prominent at score 3 (Fig. 38f) and score 4 (Fig. 38g), until a complete loss of germ 
cells in the seminiferous epithelium at score 5 of EAEO was observed (Fig. 38h). 
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Figure 38: Increased amount of apoptotic cells in EAEO testes. 
TUNEL staining on paraffin section from untreated (a), adjuvant control (b), and 
immunized mice testis, representing score 0 (c), score 1(d), score 2 (e), score 3 (f), 
score 4 (g) and score 5 (h). Arrows show apoptotic cells. Scale bars represent 100 µm. 
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3.11. BTB permeability was impaired in EAEO testes of mice 
with normal and elevated levels of follistatin 
To assess BTB integrity in testes from immunized mice, a biotin tracer penetration 
experiment was performed. Under normal conditions, in untreated (Fig. 39a) and 
adjuvant (Fig. 39b) control testes, the biotin tracer was completely restricted to the 
interstitial space and in the basal part of the seminiferous epithelium, indicating an intact 
BTB. A similar observation was made in testes of TH-immunized mice from both groups 
IV and V representing score 0 (Fig. 39c) and score 1 (Fig. 39d). The disruption of BTB 
started to be visible at score 2 (Fig. 39e) more specifically in the areas of smaller 
tubules, where the tracer infiltrated into the adluminal region of the seminiferous 
epithelium. The disruption of the BTB integrity was evident at score 3 (Fig. 39f) and 
score 4 (Fig. 39g), where the tracer extensively permeated throughout the testis, 
including the seminiferous epithelium. The complete loss of the integrity of the BTB 
accompanying the complete destruction of the morphology was visible in EAEO testes 
representing score of 5 (Fig. 39h). 
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Figure 39: Disruption of BTB integrity in EAEO testes. 
Assessment of BTB integrity using biotin tracer. The localization of the biotin tracer in 
testicular paraffin sections from untreated (a), adjuvant control (b), and TH-immunized 
mice (c - h) was directly visualized by florescence microscopy using 
streptavidin-AlexaFluor488 (green) conjugate. The images represent score 0 (c), score 
1 (d), score 2 (e), score 3 (f), score 4 (g), score 5 (h). Nuclei were counterstained with 
DAPI. Scale bars represent 50 µm. 
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3.12. FSH, LH and testosterone levels in serum 
The levels of gonadotropins and testosterone were analyzed in the serum of mice by 
RIA as shown in Figure 40. At 30 days after the first immunization, the levels of serum 
FSH were decreased in TH-immunized mice that received the FST315 vector compared 
with TH-immunized mice injected with an empty vector (EV) only (Fig. 40a). At 30 days 
after the first immunization, LH and testosterone levels were similar between all 
investigated groups, although an inter-animal biological variability was observed (Fig. 
40c and e). At 50 days after the first immunization, serum FSH and LH levels were not 
changed in any group (Fig. 40b and d). In contrast, testosterone levels were 
significantly decreased in TH-immunized mice that received an empty vector compared 
to their untreated controls, and testosterone levels were also decreased in untreated 
controls with the FST315 vector compared with untreated mice with empty vector (Fig. 
40f). 
 
 Results 
 
- 92 - 
 
 
Figure 40: Levels of FSH were lower in TH-immunized mice with elevated levels of 
follistatin whereas levels of LH and testosterone were similar between mice with 
normal and elevated levels of follistatin. 
FSH (a - b), LH (c - d) and testosterone (e - f) levels were measured in serum from 
untreated, adjuvant control and TH-immunized mice injected with empty (EV) or 
FST315 (FST) vector 30 (a, c, e) and 50 (b, d, f) days after the first immunization. Data 
are represented as mean ± SEM of 3 - 6 animals per group. Statistical analysis was 
done using one-way ANOVA followed by Tukey’s multiple comparisons for all treatment 
groups and two-way ANOVA comparing EV and FST groups followed by Sidak’s 
multiple comparisons; *P<0.05, **P<0.01; all other comparisons were not statistically 
significant. 
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3.13. Expression of steroidogenic enzymes 
Expression of steroidogenic regulators and enzymes in the testis was investigated by 
quantitative RT-PCR in order to analyze possible changes in biosynthesis of 
testosterone in the different experimental groups. At 30 days after the first 
immunizations, mRNA expression of Star (steroidogenic acute regulatory protein) (Fig. 
41a) and Hsd3b1 (hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-
isomerase cluster) (Fig. 41g) was unchanged. In contrast, Cyp11a1 (cytochrome P450, 
family 11, subfamily a, polypeptide 1) (Fig. 41c) and Cyp17a1 (cytochrome P450, family 
17, subfamily a, polypeptide 1) (Fig. 41e) mRNA transcripts were significantly 
decreased at 30 days in testes of TH-immunized mice (EAEO group) treated with 
follistatin compared with their respective untreated controls. Expression levels of 
Cyp17a1 mRNA were also decreased in adjuvant control testes from the FST315 vector 
group compared with untreated animals. Moreover, mRNA expression of Cyp17a1 was 
significantly decreased in testes of TH-immunized mice treated with follistatin compared 
with the EV group (Fig. 41e). At 50 days after the first immunization, expression of Star 
mRNA (Fig. 41b) was lower in adjuvant control EV and FST315 vector mice compared 
with their respective untreated controls. At 50 days, mRNA expression levels of 
Cyp11a1 (Fig. 41d) were similar in testes of all mice. In the FST315 vector group, at 50 
days after the first immunization, expression of Cyp17a1 (Fig. 41f) and of Hsd3b1 
(Fig. 41h) mRNA was decreased in testes of adjuvant and TH-immunized mice 
compared with their untreated controls. Overall, these results show that there is a 
general decrease of expression of the steroidogenic enzymes and regulators in testes 
of mice with elevated levels of follistatin in comparison with mice with normal levels. 
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Figure 41: Decreased mRNA expression of steroidogenic enzymes Cyp11a1, 
Cyp17a1 and Hsd3b1 in EAEO testes. 
Relative mRNA expression of Star (a-b), Cyp11a1 (c-d), Cyp17a1 (e-f) and Hsd3b1 (g-
h) in testes from untreated, adjuvant control and TH-immunized mice (EAEO group) 
injected with empty (EV) or FST315 (FST) vector 30 (a, c, e, g) and 50 (b, d, f, h) days 
after the first immunization, analyzed by quantitative RT-PCR. Data are represented as 
mean ± SEM of 3 - 5 animals per group. Statistical analysis was done using one-way 
ANOVA followed by Tukey’s multiple comparisons for all treatment groups and two-way 
ANOVA comparing EV and FST groups followed by Sidak’s multiple comparisons; 
*P<0.05 and **P<0.01, all other comparisons were not statistically significant. 
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3.14. Expression of activin and follistatin was altered in TH-
immunized mice with normal and elevated levels of follistatin 
Since activin A, inhibin and activin receptor expression was regulated in the testis 
during EAEO (study I), their systemic and testicular expression was determined in 
animals from study II by protein assays (Figures 42 and 43) and by quantitative RT-
PCR as shown in Figures 44 and 45. 
 
3.14.1. Serum levels of activin A, but not inhibin were elevated in TH-
immunized mice with normal and elevated levels of follistatin 
Levels of activin A in serum were significantly elevated in TH-immunized mice and 
injected with an empty vector (EV) or the FST315 vector (FST) by comparison with 
untreated controls at 30 days after the first immunization (Fig. 42a). The levels of activin 
A remained increased in serum from TH-immunized FST315 vector-treated mice by 
comparison with untreated controls at 50 days after the first immunization (Fig. 42b). 
Serum inhibin levels were not changed in any group at 30 (Fig. 42c) and 50 (Fig. 42d) 
days after the first immunization. 
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Figure 42: Elevated activin A but not inhibin serum levels in TH-immunized group 
30 and 50 days after the first immunization. 
Protein levels of activin A (a, b) and inhibin (c, d) were measured in serum from 
untreated, adjuvant control and TH-immunized mice (EAEO group) injected with empty 
(EV) or FST315 (FST) vector 30 (a, c) and 50 (b, d) days after the first immunization. 
Data are represented as mean ± SEM of 3-6 animals per group. Statistical analysis was 
done using one-way ANOVA followed by Tukey’s multiple comparisons for all treatment 
groups and two-way ANOVA  comparing EV and FST groups followed by Sidak’s 
multiple comparisons; *P<0.05; all other comparisons were not statistically significant. 
 
3.14.2. Expression of activin A and inhibin in testes of mice with 
normal and elevated levels of follistatin 
The expression of activin and inhibin at the protein (Figure 43) and mRNA (Figure 44) 
level was also determined in the testes.  
Testicular protein and mRNA levels of activin A (Fig. 43a and Fig. 44a, respectively) 
and inhibin (Fig. 43c and Fig. 44e, respectively) were unchanged at 30 days after the 
first immunization. At 50 days after the first immunization, an increase in mRNA levels 
of Inhba was observed in testes of TH-immunized (EAEO) FST315 vector-treated mice 
compared with their adjuvant controls (Fig. 44b), although no significant changes were 
observed in activin A protein levels (Fig. 43b). Inhibin  (Inha) mRNA levels were 
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significantly decreased in testes of adjuvant control and TH-immunized mice (EAEO) in 
the FST315 vector-treated group compared with their untreated controls and in testes of 
TH-immunized mice from the FST315 vector-treated group in comparison with testes of 
TH-immunized mice from the EV group (Fig. 44f). However, no changes in inhibin 
protein levels were observed in testes from mice from any group at 50 days after the 
first immunization (Fig. 43d). Inhbb mRNA levels were similar between all groups at 30 
(Fig. 44c) days after the first immunization. An increase of Inhbb mRNA expression was 
detected in adjuvant controls compared to untreated animals in the FST group at 50 
days after the first immunization. 
 
Figure 43: Expression of activin A and inhibin protein levels in the testis. 
Protein levels of activin A (a, b) and inhibin (c, d) were measured in testicular 
homogenates from untreated, adjuvant control and TH-immunized mice (EAEO group) 
injected with an empty (EV) or FST315 (FST) vector, 30 (a, c) and 50 (b, d) days after 
the first immunization.  Data are represented as mean ± SEM of 3 - 6 animals per 
group. Statistical analysis was done using one-way ANOVA followed by Tukey’s 
multiple comparisons for all treatment groups and two-way ANOVA comparing EV and 
FST groups followed by Sidak’s multiple comparisons. 
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Figure 44: Activin A (Inhba) subunit mRNA expression was increased and 
inhibin  subunit (Inha) mRNA expression was decreased in testes of 
TH-immunized mice (EAEO) with elevated levels of follistatin at 50 days after the 
first immunization. 
Relative mRNA expression of Inhba (inhibin A) (a-b), Inhbb (inhibin B) (c-d), Inha 
(inhibin ) (e-f) in testes from untreated, adjuvant control and TH-immunized mice 
(EAEO group) injected with empty (EV) or FST315 (FST) vector 30 (a, c, e) and 50 (b, 
d, f) days after the first immunization, analyzed by quantitative RT-PCR. Data are 
represented as mean ± SEM of 3 - 5 animals per group. Statistical analysis was done 
using one-way ANOVA followed by Tukey’s multiple comparisons for all treatment 
groups and two-way ANOVA comparing EV and FST groups followed by Sidak’s 
multiple comparisons; *P<0.05, all other comparisons were not statistically significant. 
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3.14.3. Acvr1b (ALK4) mRNA expression was decreased in 50 day 
EAEO testes mice with elevated levels of follistatin 
Acvr1b (activin receptor, type IB) and Acvr2b (activin receptor, type IIB) mRNA 
expression in testes was unchanged in any group at 30 days after the first immunization 
(Fig. 45a and c). Likewise, Acvr2b mRNA levels at 50 days after the first immunization 
were similar between all groups (Fig. 45d). Acvr1b mRNA expression was significantly 
decreased in testes of adjuvant and TH-immunized mice by comparison with untreated 
controls in the FST315 vector-treated group at 50 days after the first immunization (Fig. 
45b). 
 
Figure 45: Decreased mRNA expression of Acvr1b in 50 day EAEO testes from 
mice with elevated levels of follistatin. 
Relative mRNA expression of Acvr1b (activin receptor, type IB) (a-b) and Acvr2b 
(activin receptor, type IIB) (c-d) in testes from untreated, adjuvant control and 
TH-immunized mice (EAEO group) injected with empty (EV) or FST315 (FST) vector 30 
(a, c) and 50 (b, d) days after the first immunization, analyzed by quantitative RT-PCR. 
Data are represented as mean ± SEM of 3 - 5 animals per group. Statistical analysis 
was done using one-way ANOVA followed by Tukey’s multiple comparisons for all 
treatment groups and two-way ANOVA comparing EV and FST groups followed by 
Sidak’s multiple comparisons; *P<0.05, all other comparisons were not statistically 
significant. 
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3.14.4. Follistatin mRNA expression was upregulated in 50 day EAEO 
mouse testes after follistatin treatment 
At 30 days after the first immunization, protein and mRNA levels of follistatin (Fig. 46a, 
c, e and g) were unchanged in any group. In contrast, 50 days after the first 
immunization, follistatin protein levels were significantly elevated in testes of 
TH-immunized mice from the FST315 vector-treated group compared with untreated 
controls, but also by comparison with testes of TH-immunized mice from the EV group 
(Fig. 46b). However mRNA levels of total follistatin (Fst) (Fig. 46d) and the two splice 
variants Fst288 (Fig. 46f) and Fst315 (Fig. 46h) were similar in all groups at 50 days 
after the first immunization. 
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Figure 46: Elevated levels of follistatin in 50 day EAEO testes after follistatin 
treatment. 
Protein levels of follistatin (a-b), and relative mRNA expression of Fst (c-d), Fst288 (e-f) 
and Fst315 (g-h) were measured in testicular homogenates from untreated, adjuvant 
control and TH-immunized mice (EAEO group) injected with empty (EV) or FST315 
(FST) vector 30 (a, c, e, g) and 50 (b, d, f, h) days after the first immunization. Data are 
represented as mean ± SEM of 3 - 5 animals per group. Statistical analysis was done 
using one-way ANOVA followed by Tukey’s multiple comparisons for all treatment 
groups and two-way ANOVA comparing EV and FST groups followed by Sidak’s 
multiple comparisons; *P<0.05, all other comparisons were not statistically significant. 
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3.15. Expression of activin A, follistatin and inflammatory 
markers showed strong correlation with EAEO score  
Based on the above described results, it was relevant to perform correlations in order to 
elucidate if there is any causal statistical relationship between activin A expression 
(Figure 47), follistatin expression (regardless of treatment with FST315 vector) (Figure 
48) or EAEO development (Figure 49). 
Table 6 summarizes the most significant correlations observed between activin A and 
follistatin expression and EAEO score. 
 
Table 6: Summary of the EAEO parameters correlating with expression of 
testicular activin A, testicular follistatin and EAEO score.  
 
+: positive correlation, no: no correlation. Analysis was done using Pearson’s correlation 
between each two variables. Values from adjuvant control and EAEO mice injected with 
empty (EV) or FST315 (FST) vector, at 50 days after the first immunization were used 
for the statistical analysis. 
 
Testicular activin A protein expression was positively correlated with testicular follistatin 
protein levels (Fig. 47a), as well as with activin A expression in the serum (Fig. 47b), 
with Inhba mRNA relative expression (Fig. 47c), and with the TNF mRNA levels (Fig. 
47d). These data indicate that higher testicular activin A levels are associated with 
higher follistatin testicular levels, activin serum levels and TNF expression in the testis. 
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Figure 47: Testicular follistatin protein levels; serum activin A levels, Inhba and 
TNF mRNA expression were positively correlated with testicular activin A protein 
levels 50 days after the first immunization. 
Testicular follistatin protein levels (a), serum activin A protein levels (b), Inhba (b) and 
TNF (d) mRNA levels were correlated with testicular activin A protein levels 50 days 
after the first immunization of adjuvant control and TH-immunized mice (EAEO group) 
injected with empty (EV) or FST315 (FST) vector. r represents Pearson’s correlation 
coefficient. Pearson’s correlation was considered statistically significant at *P<0.05. 
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Testicular follistatin protein levels were positively correlated with its own testicular 
mRNA expression levels (Fig. 48a, b and c), and the inflammatory mediators TNF (Fig. 
48d), IL-10 (Fig. 48e) and MCP-1 (Fig. 48f). This means that higher follistatin levels in 
the testis were associated with higher expression of inflammatory mediators, such as 
TNF, IL-10 and MCP-1. 
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Figure 48: Testicular follistatin, TNF, IL-10, MCP-1 mRNA levels were positively 
correlated with testicular follistatin protein levels, 50 days after the first 
immunization. 
Relative mRNA expression of Fst (a), Fst288 (b), Fst315 (c), TNF (d), IL-10 (e) and 
MCP-1 (f) were correlated with testicular follistatin protein levels 50 days after the first 
immunization of adjuvant control and TH-immunized mice (EAEO group) injected with 
empty (EV) or FST315 (FST) vector. r represents Pearson’s correlation coefficient. 
Pearson’s correlation was considered statistically significant at *P<0.05. 
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Finally, the score of EAEO was positively correlated with serum (Fig. 49a) and testicular 
activin A protein (Fig. 49b) and mRNA levels (Fig. 49c), as well as with the 
inflammatory mediators TNF (Fig. 49d), IL-10 (Fig. 49e) and MCP-1 (Fig. 49f). This 
means that higher levels of testicular and serum activin A are associated with higher 
severity of inflammation, characterized by the expression of the inflammatory mediators, 
such as TNF, IL-10 and MCP-1, and higher degree of development of EAEO and 
histological damage of the testis. 
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Figure 49: Serum and testicular activin A protein and mRNA levels; TNF, IL-10 
and MCP-1 mRNA levels were positively correlated with EAEO score 50 days after 
the first immunization. 
Serum activin A levels (a), testicular activin A protein (b) and mRNA (Inhba) levels (c), 
TNF (d), IL-10 (e) and MCP-1 (f) mRNA levels were positively correlated with EAEO 
score 50 days after the first immunization of adjuvant control and TH-immunized mice 
(EAEO group) injected with empty (EV) or FST315 (FST) vector. r represents Pearson’s 
correlation coefficient. Pearson’s correlation was considered statistically significant at 
*P<0.05. 
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3.16. Expression of activin A by peritubular and Sertoli cells 
after treatment with inflammatory mediators 
Treatment of peritubular cells with different concentrations of TNF for 24 hours (Fig. 
50a) showed no effect on production of activin A. 
Treatment of Sertoli cells with TNF for 48 hours (Fig. 51a) showed a dose-dependent 
increase in the production of activin A. The dose response from the third isolation of 
cells was taken as a representative result. It shows that the highest production of activin 
A by the Sertoli cells was obtained with a concentration of around 25 ng/ml of TNF. A 
50% production of activin A by the Sertoli cells was seen at a concentration of TNFof 1 
ng/ml. 
Treatment of peritubular cells (Fig. 50b) and Sertoli cells (Fig 51.b) with different 
concentrations of recombinant activin A showed an increase of the activin A production 
starting at a concentration of 12.5 ng/ml treatment. The increase is proportional to the 
dose of recombinant activin A with which the cells were treated and that is present in 
the medium. The activin A detected by the assay could be the recombinant activin A 
used for the treatment instead of the endogenous activin A produced by the cells. 
 
Figure 50: Activin A production by cultured mouse peritubular cells. 
Activin A (a-b) was measured in the media of peritubular cells treated with recombinant 
TNF (a) or recombinant activin A (b) for 24 hours. Data are represented as mean ± 
SEM of 1 - 3 separate experiments. 
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Figure 51: Activin A production by cultured mouse Sertoli cells. 
Activin A (a-b) was measured in the media of Sertoli cells treated with recombinant TNF 
(a) or recombinant activin A (b) for 48 hours. Data are represented as mean ± SEM of 1 
- 4 separate experiments. 
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4. DISCUSSION 
This study provides evidence that, in a mouse model of testicular inflammation (EAEO), 
the levels of activin A in the testis are elevated during the course of the disease. A 
positive correlation between testicular activin A protein levels and the severity of the 
disease was found.  
Furthermore, increased levels of activin A were accompanied by significantly 
upregulated expression of testicular follistatin during the active and chronic stages of 
EAEO (50 and 80 days, respectively). Moreover, the data show evidence that follistatin 
treatment of mice (using a FST315 vector to elevate circulating follistatin levels) before 
induction of EAEO, led to a slightly reduced induction rate of the disease, although there 
was no correlation between testicular follistatin expression and EAEO score. 
 
In order to mimic the manifestation and symptoms of human testicular inflammation in 
an animal model and to transfer it to transgenic animal models in the future, C57BL/6N 
and J mouse strains were selected. In this study, a mouse model for induction of EAEO 
was utilized, mimicking some forms of human immunological infertility following a 
modified well-established protocol using TH in combination with adjuvants and 
Bordetella pertussis toxin (“classical” induction). This protocol has been used previously 
in rats and mice (Doncel et al., 1989, Fijak et al., 2005, Aslani et al., 2015, Tung et al., 
1987). 
 
Data presented here show that immunization with testicular homogenate (TH) in 
combination with complete Freund’s adjuvant and Bordetella pertussis toxin leads to 
more severe autoimmune reaction / inflammation than immunization with TH only 
without adjuvants (Musha et al., 2013). Studies using different immunization protocols 
have proven the importance of using adjuvants and B. pertussis toxin for the successful 
induction of EAEO. Adjuvants are used in order to activate and boost the immune 
system, while B. pertussis toxin triggers inflammation as a co-adjuvant and mitogen. It 
also has been shown that B. Pertussis toxin increases the permeability of the 
blood-brain-barrier during the induction of another rodent model of autoimmune 
disease, experimental autoimmune encephalomyelitis (EAE) (Linthicum et al., 1982). 
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However, the toxin concentration required to induce EAE was 2-3 times higher (200-300 
ng toxin per mouse), than used here for the induction of EAEO (100 ng per mouse) 
(Puentes et al., 2013, Prinz-Hadad et al., 2013). This concentration was far below the 
LD50 dose (17 μg/kg body weight) in mice (Sidey et al., 1989, Parton, 1985).  
B. pertussis toxin shows pleiotropic effects on the immune system, such as triggering of 
T-cell mitosis and increase in cytokine production and antibodies (Morse et al., 1977, 
Munoz et al., 1981). In addition, microbial products like B. Pertussis toxin amplify the 
interaction between the innate and adaptive immune system. It was also reported that 
the toxin promotes an immune response against autoantigens in the initiation of 
autoimmune diseases like EAE (Hofstetter et al., 2002). 
 
In order to analyze the induction rate, development and progression of the disease, the 
histopathologic and expression profiles of inflammatory mediators (TNF, IL-6, IL-10 and 
MCP-1), known to be involved in EAEO pathology in rats, were examined. According to 
the histopathological examination and immune profile of the animals, observations from 
this study were in line with the existing data in a rat model of EAEO, which has been the 
most broadly used model for studying autoimmune-based testicular inflammation (Fijak 
et al., 2011b, Doncel et al., 1989). The results presented here recapitulate the process 
of development and progression of the disease leading to degeneration of the testicular 
architecture in late and chronic stage of EAEO in mice during three different time points, 
e.g. 30, 50 and 80 days after the first immunization. Firstly, at 30 days, only a small 
number of the immunized mice (1 of 3 mice from study I and 2 of 5 mice from study II) 
showed histological symptoms of EAEO. Secondly, at 50 and 80 days all animals from 
study I, immunized with TH in CFA and B. pertussis toxin developed testicular 
inflammation with all the characteristics of the disease. In contrast, only 50% animals 
from study I, immunized with TiterMax Gold developed the disease. Induction of EAEO 
as performed in study II, using CFA for the first immunization and IFA for two following 
boost immunizations also resulted in a lower induction rate than in mice from study I 
injected three times with TH in CFA. These findings indicate that CFA seems to be the 
most effective adjuvant in inducing EAEO in C57BL/6 mouse strain. This could be due 
to the presence of killed Mycobacterium tuberculosis in the composition of this adjuvant. 
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Unfortunately, the use of CFA for the three subsequent immunizations was not possible 
in study II due to the local regulations of the Monash University animal Ethics 
committee. Moreover, the induction rate of EAEO at 50 days after the first immunization 
in animals from study II was of 40% for mice treated with the follistatin vector and 75% 
for mice injected with an empty vector. These results show that follistatin treatment has 
a potential effect on diminishing the induction of the disease. Furthermore, this induction 
rate was comparable to the induction rate mentioned in described studies in mice (e.g. 
89% in C57BL/6N, 68% in B6AF1 or 92% in BALB/cBy strains) (Tung et al., 1987, Yule 
et al., 1988, Teuscher et al., 1985). 
Even though mice treated with the follistatin vector showed a lower induction rate of 
EAEO compared with mice injected with the empty vector, it is important to mention that 
the morphological changes found in the testis during the course of the disease were 
similar in both studies I and II. The affected testes showed an accumulation of immune 
cells, disruption of the testicular morphology with a significant reduction of the diameter 
of the seminiferous epithelium, disruption of the BTB, which was first observed at EAEO 
score of 2, based on the assessment criteria described in this study, together with 
increased apoptosis and sloughing of germ cells and tubular atrophy leading to a 
significantly smaller testis size. 
 
Apart from the different adjuvants used, another explanation for the differences in the 
induction rate of EAEO between the different treatment groups from study I and mice 
from study II with normal levels of follistatin could be due to the use of the different 
strains of mice (C57BL/6N and C57BL/6J). Previous studies describing induction of 
EAEO using one protocol, but different mouse strains suggested that the high 
susceptibility to the disease induction in mice seems to be also strain specific 
(Tokunaga et al., 1993, Teuscher et al., 1985). 
 
The findings in this study show that the modified immunization protocol used here with 
CFA for three subsequent immunizations, leads to a higher induction rate of EAEO in 
mice (100%) compared with previously described studies (Tung et al., 1987, Yule et al., 
 Discussion 
 
- 113 - 
 
1988). Moreover, the results establish that CFA is the most potent adjuvant for inducing 
EAEO in a very severe form. 
 
For the first time, this study shows that the observed morphological changes in EAEO 
testes were accompanied by a strong peritubular fibrotic response represented by an 
increase of collagen fibers around the seminiferous tubules. In addition to the collagen 
deposits, there was a change in the morphological distribution and thickening of the 
SMA layer in the peritubular cells. It can be hypothesized that the inflammatory 
process in the testis and subsequent disruption of the testicular morphology led to a 
change of the function of peritubular cells and fibrotic response, as seen in human 
testicular biopsies from patients with impaired spermatogenesis (Mayerhofer, 2013). 
Adam et al., showed that peritubular cells are important players involved in the process 
leading to fibrotic response in the testis (Adam et al., 2011). Notably, the collagen 
deposits in testes from animals developing low grade EAEO (a score of 2) were less 
prominent as by comparison with the severe form at the later stages of the disease 
(score of 3 and higher). Moreover, very strong formation of collagen deposits was 
observed in close proximity to the areas with inflammatory infiltrates, granulomas and 
disturbed testicular morphology. This observation was not surprising as there is also an 
accumulation of mast cells in the areas with leukocytic agglomeration. In fact, mast cells 
are known to play a role in inducing fibrosis (Wilgus and Wulff, 2014). It is thought that 
mast cells have a detrimental effect in many inflammatory diseases including 
experimental colitis, EAE, arthritis or lung fibrosis (Wernersson and Pejler, 2014). In 
regard to the fibrotic response, it is also important to note that the mRNA levels of 
collagen I, alpha 1 (a marker of fibrosis) were highly elevated in EAEO testes at a score 
of 5. 
 
The data also point to a possible involvement of immune cells in the generation of 
fibrotic testicular response. Observations regarding morphology and fibrotic response 
suggest that the active phase of EAEO starts after the third immunization period and the 
severe form of the disease is reached around 50 days after the first immunization, 
followed by the chronic form at 80 days. Fibrosis is involved in a process of tissue repair 
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after inflammation induced cellular destruction, however the uncontrolled fibrosis leads 
to serious health impairment, as occurs in idiopathic pulmonary fibrosis, cirrhosis of the 
liver or renal failure (reviewed in (Hedger et al., 2011). Therefore, testicular fibrosis 
could be leading to ill health of the organ and its function.   
 
As EAEO is a T cell mediated disease, the findings also show the increase of the T cell 
population in EAEO testis with a novel characterization of the T cell subtypes. In the 
investigated mouse model of EAEO, an increase of the number of infiltrating leukocytes 
(CD45+) in the testicular interstitial space was observed consisting mainly of 
macrophages and T cells. A similar increase in leukocytic accumulation in inflamed 
testes has already been described in a rat model of EAEO (Jacobo et al., 2011). 
Interestingly, in rat EAEO testes, the population of CD4+ and CD8+ T effector cells was 
increased at the onset of the disease with a predominating population of CD4+ T cells. 
During the severe phase of the disease, the CD4+ T cell subset decreased, whereas 
CD8+ T cells were unchanged (Jacobo et al., 2009). In contrast, in the present mouse 
model of EAEO, highly elevated numbers of CD4+ T cells were observed, whereas the 
population of CD8+ T cells was significantly decreased at 50 days. The data was 
supported by a higher ratio of CD4+/CD8+ T cells in the testis, which was comparable 
to many other immune disorders and diseases. In fact, this ratio can also be used as a 
diagnostic tool for several inflammatory diseases such as infectious mononucleosis, 
chronic lymphocytic leukemia, Hodgkin disease, anemia or autoimmune neurological 
disorders like multiple sclerosis (Hernandez et al., 2005, Stuve et al., 2006). An 
increase in the number of activated T cells (CD4+CD25+) was also recorded in inflamed 
testes which was consistent with the increase of these cells observed in a rat model of 
EAEO (Guazzone et al., 2009). 
 
Furthermore, a novel finding of the study was the detection of existence of double 
positive CD4+CD8+ T cells in the inflamed testis. Initially thought to be exclusively 
present in the thymus as an immature stage of T cell development, CD4+CD8+ cells 
have been identified recently in other organs (Overgaard et al., 2015). Up to now, the 
function of these cells in the periphery has not been very well investigated and remains 
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controversial. There are reports showing an increase in the number of CD4+CD8+ T cell 
subsets in autoimmune and chronic inflammatory disorders, namely in peripheral blood 
and synovium from patients with rheumatoid arthritis (Quandt et al., 2014), in fibrotic 
skin lesions from patients with systemic sclerosis (Parel et al., 2007), or in the liver from 
patients with hepatitis B and C (Nascimbeni et al., 2011). Further functional studies are 
necessary for deeper examination of CD4+CD8+ double positive T cells to fully 
elucidate their contribution to the immune response and spermatogenic damage in 
mouse inflamed testes.  
In addition, the results show that not only the amount of macrophages is increased in 
EAEO testes but that the main population of macrophages possesses a pro-
inflammatory M1 phenotype. In fact, under normal conditions in rodent testes, resident 
macrophages represent a significant population of interstitial cells (Niemi et al., 1986). 
Most of them are anti-inflammatory M2 macrophages that display an 
immunosuppressive profile, putatively are specialized in providing protection for the 
developing germ cells and are involved in maintaining the immune privilege of the testis 
(Fijak and Meinhardt, 2006, Bhushan et al., 2015). In the present mouse model of 
EAEO, it has been confirmed that macrophages in control testes possess mainly an M2 
phenotype, as they co-express the F4/80 and CD206 markers. Under inflammatory 
conditions, in EAEO mouse testes, there is an evident increase in the number of 
macrophages, as described in an EAEO model in BALB/c and C57BL/6 mice (Yule et 
al., 1988) and in rats (Rival et al., 2008, Fijak et al., 2005). The majority of the 
macrophages in EAEO testes do not express the CD206 marker. This finding suggests 
that the main population of macrophages in EAEO mouse testes possesses a pro-
inflammatory M1 phenotype. This is in agreement with several reports showing the 
inflammatory phenotype and pathogenic role of macrophages in rat EAEO (Rival et al., 
2008, Guazzone et al., 2003). In this light, it is important to mention that testicular 
activin A could be also involved in the process of macrophage phenotype determination 
during inflammatory conditions by inducing transition between M1 and M2 phenotypes, 
knowing that M1 are pro-inflammatory and M2 are pro-fibrotic (Hedger and de Kretser, 
2013). 
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Furthermore, TNF, a strong pro-inflammatory cytokine, was significantly increased in 
our models of EAEO, similar to another mouse model of testicular inflammation induced 
by viable germ cells alone (Terayama et al., 2011). A significant increase was also 
detected in testicular mRNA levels for MCP-1, a potent chemokine, involved in 
recruiting the macrophages to the site of inflammation (Deshmane et al., 2009). Similar 
findings were also reported in a rat model of EAEO (Guazzone et al., 2003, Fijak et al., 
2011b). Notably, the significant increase of TNF and MCP-1 was only observed in 50 
day EAEO testes of mice with normal levels of follistatin, when compared to mice 
treated with follistatin. The elevation of these inflammatory mediators was also observed 
in testes from follistatin treated mice although not significant. These data suggest that 
follistatin treatment could have an effect on suppressing the inflammatory response in 
EAEO testis. Interestingly, the testicular expression of TNF and MCP-1 was diminished 
at 80 days of EAEO compared to their expression at 50 days of EAEO, but was still 
significantly elevated by comparison with the controls.  
In contrast to earlier reports in rat EAEO (Rival et al., 2006b, Fijak et al., 2011b), the 
mRNA levels of IL-6 were not elevated during the course of testicular inflammation in 
the mouse model of EAEO induced by three immunizations with CFA. Nonetheless, IL-6 
mRNA levels were significantly elevated in 50 day EAEO testes of mice treated with 
follistatin compared with mice with normal levels of follistatin. 
 
Moreover, this study confirms previous findings showing that activin A is located mainly 
within the Sertoli cells and some interstitial cells in normal testes, most likely 
macrophages and less prominently in the Leydig cells, as it is known that they produce 
activin A (Ebert et al., 2007).  
As a novel finding, this study shows that, under inflammatory conditions, activin A is 
strongly expressed by Sertoli cells and infiltrating immune cells within the inflamed 
EAEO testis (50 days). Notably, in the late stage of the disease at 80 days, no 
significant increase in the levels of activin A either at mRNA or protein level was 
observed in EAEO testes. Previous reports have shown that activin A levels are 
elevated in numerous chronic diseases like colitis, meningitis, cancer or autoimmune 
based diseases like arthritis (Michel et al., 2003, Jorgensen et al., 2014, Phillips et al., 
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2009, Zhang et al., 2009). The results obtained in this study have shown that testicular 
activin A was also elevated in a mouse model of autoimmune-based testicular 
inflammation with a significant increase in the severe form of the disease at 50 days. 
Moreover, activin A was also elevated in the serum of animals from study II developing 
EAEO starting from 30 days after the first immunization and the levels remained 
elevated at 50 days after the first immunization in the serum of animals treated with 
follistatin. The findings suggest that activin A may be involved in the development of 
autoimmune orchitis, as it has been shown to regulate inflammation and immunity in 
many tissues (Hedger et al., 2011). Furthermore, the increase of activin A coincided 
with the elevated expression of inflammatory mediators like TNF and MCP-1. 
Additionally, an increase of testicular activin B and inhibin protein levels in the severe 
form of the disease in mice from study I was observed, but the mRNA levels of the 
and B subunit forming mainly inhibin B were decreased at 80 days. Moreover, 
mRNA levels of the subunit of inhibin was also decreased in EAEO testes of mice 
treated with follistatin compared with their controls and with EAEO testes of mice with 
normal levels of follistatin. A similar observation was reported in a rat model of EAEO, 
demonstrating decreased levels of circulating inhibin B as well as a decreased inhibin 
 subunit expression in Sertoli cells (Suescun et al., 2001). 
In addition, it is known from a rat model, that FSH levels are increased during EAEO 
(Suescun et al., 1994, Fijak et al., 2011b). This increase could be caused by the loss of 
inhibin production observed in the EAEO testis. LH levels were also increased in our 
mouse model of EAEO similarly to the rat model (Fijak et al., 2011b). Interestingly, at 
30 days after the first immunization, FSH levels were significantly lower in mice treated 
with follistatin compared to mice with normal levels of follistatin. Knowing that activin A 
is involved in the HPG axis and in stimulating the production of FSH by the pituitary, it is 
only natural to see a decrease of FSH levels after follistatin treatment as the production 
of FSH by the pituitary will be indirectly inhibited through blockage of activin A and its 
stimulatory effect. 
Moreover, testosterone circulating levels were decreased in 50 day EAEO testes of 
mice with normal levels of follistatin compared with their untreated controls which is in 
agreement with the observation seen in a rat model of the disease (Fijak et al., 2011b, 
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Suescun et al., 1994). A decrease in testosterone levels in untreated mice with elevated 
levels of follistatin was also observed compared with untreated mice with normal levels 
of follistatin, which could mean that follistatin treatment could have an effect on 
testosterone production. Additionally, an intra-animal variability of testosterone levels 
was observed; therefore changes in steroidogenic enzymes reflecting the function of 
Leydig cells in the testis were examined. A decrease in the mRNA expression of 
Cyp11a1, Cyp17a1 and Hsd3b1 was observed in EAEO testes compared with controls. 
This result was a direct indication and a confirmation of the observed decrease of 
testosterone levels. 
 
Curiously, the levels of activin A receptors: ALK4 (Acvr1b) and the activin receptor 
type 2 subunit (Acvr2b) in the inflamed testis were significantly lower than in normal 
testis, while activin A levels were higher. It is likely that high activin A levels lead to a 
negative feedback on the receptor expression levels. 
 
It was also shown in this study, that the increase of activin A was accompanied by an 
increase of follistatin expression in the inflamed testis. This observation is in line with 
data from the literature showing that activin A can induce expression of follistatin (Jones 
et al., 2000). A possible explanation for this observation would be that the increase of 
the follistatin levels may act to counter the effects of activin A during the disease 
thereby decreasing the severity of the inflammation. The present data demonstrate that 
higher levels of testicular follistatin at 50 days of EAEO are able to block the increase of 
activin A expression at 80 days. However the inhibitory function of follistatin at this stage 
of the disease does not lead to the resolution of inflammation at 80 days. It is likely that 
the positive effect of follistatin on inhibition of inflammation will be visible at later time 
points.  
 
It is known that activin A causes muscle wasting and cachexia (Chen et al., 2016, Chen 
et al., 2014). Moreover, follistatin induces muscle hypertrophy by inhibiting the action of 
myostatin (Barbe et al., 2015). Nowadays, follistatin is being used as a therapy for 
skeletal muscle atrophy (Sepulveda et al., 2015). Therefore, it was not surprising to see 
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that mice that received the follistatin vector in their tibialis anterior muscle presented 
with muscle hypertrophy at the site of injection of the FST315 vector in mice from 
study II. 
 
Furthermore, a 5-fold elevation of circulating follistatin levels in mice from study II, 
30 days after the vector injection, did not lead to a change in activin A serum levels. It 
should be noted that the levels of activin A detected by ELISA could already be 
neutralized by follistatin as it is bound to activin A. Nonetheless, 30 days after the 
induction of EAEO, activin A serum levels were significantly higher in TH-immunized 
mice compared with their untreated controls regardless of follistatin treatment. This 
increase in activin A serum levels was still observed in TH-immunized mice compared 
with untreated controls even at 50 days after the first immunization, but only for mice 
treated with follistatin. This result shows that elevating systemic follistatin levels did not 
alter the levels of activin A in the serum of mice that developed EAEO, giving an 
additional proof that mice developing EAEO produce substantially more activin A. 
Moreover, the increase of circulating follistatin levels in mice did not notably alter the 
testicular levels of activin A, although a slight reduction of activin A protein levels was 
observed EAEO testes of mice treated with follistatin compared with mice that had 
normal levels of follistatin at 50 days after the first immunization. This decrease of 
activin A levels was consistent with the significant increase of follistatin testicular levels 
in EAEO of mice treated with follistatin compared to their untreated controls and also to 
EAEO testes of mice with normal levels of follistatin. On the other hand, mRNA levels of 
activin A remained significantly higher in EAEO testes of mice treated with follistatin 
compared to their adjuvant controls at 50 days after the first immunization. 
These results demonstrate that elevating follistatin circulating levels had a negative 
effect on activin A production in the testis and therefore led to a lower induction rate of 
EAEO but did not completely prevent the induction of EAEO in these mice. In fact, it 
was observed that mice with elevated levels of follistatin had a lower induction rate of 
EAEO of 40%, and higher testis weights at 50 days after the first immunization, 
compared with and induction rate of 75% in animals with normal levels of systemic 
follistatin that had significantly reduced testis weights.  
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Different variables such as expression of activin A, follistatin and inflammatory markers 
(TNF and MCP-1) were correlated with regard to EAEO development. These 
correlations show that, when activin A levels are elevated, there is a severe testicular 
inflammation, which leads to a higher EAEO score. Interestingly, the EAEO did not 
correlate with testicular follistatin levels, which point out that the development of the 
disease could be independent of testicular follistatin expression. 
Therefore, data from this study suggest that treatment of EAEO by simply increasing the 
systemic levels of follistatin does not completely inhibit disease development, although it 
leads to a lower induction rate of EAEO in treated mice. Knowing the fact that testicular 
inflammation is a local disease, it could be speculated that a local treatment with 
follistatin, at the site of the inflammation directly would be more effective than elevating 
circulating follistatin levels. 
Moreover, these observations lead to the assumption that the induction and 
development of orchitis requires a well-orchestrated action between activin and 
inflammatory mediators. In fact, each molecule, at a certain concentration, plays a role 
during the inflammation and its’ role is dictated by the presence of the other players 
involved such as activins, follistatin, inflammatory markers, immune cell, fibrotic markers 
and others. 
 
Finally, an in vitro study with primary Sertoli and peritubular cells treated with cytokines 
(activin A, TNF) that were elevated in the present mouse model of EAEO was 
undertaken, in order to mimic the inflammatory milieu in EAEO testis. Firstly, our results 
suggest that the optimal dose for treating SC with TNF is 25 ng/ml since the cells 
treated with the above mentioned concentration show the highest activin A production. 
Secondly, as TNF stimulates production of activin A by SC, and acts through MAPK and 
NFB signaling (Takada and Aggarwal, 2004), it promotes inflammation and therefore 
additional activin A expression by these cells. In order to determine if treatment with 
activin A affects SC and PTC through activating activin signaling, it would be necessary 
to study the activation of the SMAD signaling in these cells by performing a SMAD 
Western Blot. Further in vitro experiments are necessary, such as treatment of cells with 
a mixture of the different inflammatory markers should be performed in order to pin 
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down the existence of a synergistic or additive effect of the cytokines on the function of 
the cells by evaluating the activation of the activin signaling pathway, the expression of 
activin receptors and the expression of fibrotic genes (SMA and collagen type I, 
alpha I). 
 
Taken together, our findings point to a pro-inflammatory role for activin A in a mouse 
model of testicular inflammation, having a synergistic effect with other elevated 
inflammatory mediators (TNF, MCP-1 and interleukins). Furthermore, detailed 
mechanistic and functional studies are necessary to understand the exact role of 
activins and their functional antagonists, inhibin and follistatin, in this process leading to 
severe inflammation causing infertility. 
 
In conclusion, testicular autoimmune orchitis is a complex disease which involves 
multiple mechanisms for the promotion and the development of the histopathological 
changes observed in the testis, an immune privileged organ. These mechanisms 
involved in orchitis development represent a direct relation between activin and 
follistatin expression on one hand and factors characterizing the disease on the other 
hand, such as immune cell infiltration and accumulation, overexpression of inflammatory 
markers, loss of the BTB integrity and disruption of the immune privilege, strong fibrotic 
formation and apoptosis of germ cells with destruction of the seminiferous epithelium. 
Taken together, these different effectors work synergistically to promote orchitis and 
lead to irreversible infertility. Follistatin could be utilized as a potential therapeutic 
together with other anti-inflammatory drugs in order to diminish the severity of the 
disease and to restore fertility. 
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5. APPENDIX 
 
5.1. MATERIALS 
 
5.1.1. Cell culture reagents and equipment 
48 well Costar cell culture plates (#3548)   Corning, NY, USA 
75cm2 cell culture flasques (#430641)   Corning,NY, USA 
Bovine serum albumin (#7030) Sigma, St Louis, USA 
CO2 incubator HeraCell, Heraeus Thermofischer Scientific, Waltham, 
MA, USA 
DMEM (#10965-084)      Gibco, Grand Island, NY, USA 
DMEM+GlutaMAX (#10566-016)    Gibco, Grand Island, NY, USA 
DMEM/F12+GlutaMAX (#10565-042)   Gibco, Grand Island, NY, USA 
Dulbecco´s PBS (1X) w/o CaCl2 & MgCl2 (#14190-144) Gibco, Grand Island, NY, USA 
Dulbecco´s PBS (10X) with CaCl2 & MgCl2 (#14080-055) Gibco, Grand Island, NY, USA 
Fetal Bovine Serum (FBS) (#16000-044)   Gibco, Grand Island, NY, USA 
Laboratory water bath Thermoline, Smithfield, NSW, 
Australia 
L-Glutamine 200 mM (#25030-081)    Gibco, Grand Island, NY, USA 
MEM Non-Essential Amino Acids (#11140-050)  Gibco, Grand Island, NY, USA 
Neubauer Counting Chamber    Boeco, Hamburg, Germany 
Penicillin/Streptomycin (#15140-122)   Gibco, Grand Island, NY, USA 
Recombinant human/mouse/rat activin A (338-AC/CF) R&D systems, Minneapolis, USA 
Recombinant mouse CCL2/JE/MCP-1 (479-JE-010/CF) R&D systems, Minneapolis, USA 
Recombinant mouse IL-6 (406-ML-005/CF) R&D systems, Minneapolis, USA 
Recombinant mouse TNF (aa 80-235) R&D systems, Minneapolis, USA 
Shaking water batch (RW1812) Paton Scientific, SA, Australia 
Trypan blue solution 0.4%     Sigma, St Louis, USA 
TrypLE Express (#2605-028)     Gibco, Grand Island, NY, USA 
 
5.1.2. Chemicals 
Acetic acid, glacial      Merck, Darmstadt, Germany 
Acid fuchsin, 1% aqueous     BDH (now Merck), Poole, UK 
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Agarose        Invitrogen, Karlsruhe, Germany 
Ammonium solution 25%      Merck, Darmstadt, Germany 
Ammonium sulfate      Merck, Darmstadt, Germany 
Aniline oil (#UN1547)      VWR, Fontenay-ss-bois-France 
Aniline Blue (#1279)      Merck, Darmstadt, Germany 
Azocarmin G solution (#1A266) Chroma-Gesellschaft, Stuttgart, 
Germany 
Benzoid acid methyl ester (#6944.1)    Carl Roth, Karlsruhe, Germany 
Biebrich scarlet, 1% aqueous     BDH (now Merck), Poole, UK 
-mercaptoethanol Sigma, Saint Louis, USA 
Bordetella pertussis toxin salt-free toxin (516562) Calbiochem, Darmstadt, Germany 
Bouin’s Fixative Solution (#BOUN-1L) Amber Scientific, Midvale, WA, 
Australia 
Calcium Chloride CaCl2 (#C5080-500G) Sigma, St Louis, USA 
CAS block histochemical reagent Life technologies, Frederick, USA 
Celestine blue BDH (now Merck), Poole, UK 
Citric acid (244)      Merck, Darmstadt, Germany 
DPX mounting medium Merck, Darmstadt, Germany 
Entallan new mounting medium (#107961) Merck, Darmstadt, Germany 
Ethanol        Sigma, Steinheim, Germany 
Ethidium bromide       Roth, Karlsruhe, Germany 
Ethylene diaminetetraacetic acid disodium salt (EDTA) Merck, Darmstadt, Germany 
Eukitt Quick hardening mounting medium   Sigma-Aldrich, Saint Louis, USA 
EZ-Link® Sulfo-NHS-LC-Biotin (21335) Thermoscientific, Rockford, USA 
Ferric Ammonium Sulphate Ajax Finechem, Seven Hills, NSW, 
Australia 
Ferric Chloride Ajax Finechem, Tarren Point, NSW, 
Australia 
Formaldehyde solution 37%      Merck, Darmstadt, Germany 
Formalin       Trajan, Ringwood, Vic, Australia 
Freund’s adjuvant, complete     Sigma, Saint Louis, USA 
Freund’s adjuvant, incomplete Sigma, Saint Louis, USA 
Glycerin Ajax Finechem, Taren Point, NSW, 
Australia 
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Glycine        Sigma, Steinheim, Germany 
Harris Hematoxylin Solutions, Modified (#HHS16) Sigma, St Louis, USA 
Hydrochloric acid, concentrated    Merck, Munich, Germany 
Hydrochloric acid 37%      Sigma, Steinheim, Germany 
Hydrogen peroxide 30% (H2O2 30%) (#8070.1) Carl Roth, Karlsruhe, Germany 
Isopentane (#103614T) AnalaR NORMAPUR, VWR 
international DBH, Fontenay-sous-
bois, France 
Isoflurane        Baxter, Unterschleißheim, Germany 
Mayer's hematoxylin solution     Merck, Darmstadt, Germany 
Methanol        Sigma, Steinheim, Germany 
Orange G (#15925)      Merck, Darmstadt, Germany 
Paraformaldehyde       Merck, Darmstadt, Germany 
Periodic acid Amber Scientific, Midvale, WA, 
Australia 
Phosphotungstic acid Ajax Finechem, Tarren Point, NSW, 
Australia 
Picric acid        Merck, Darmstadt, Germany 
Potassium chloride       Merck, Darmstadt, Germany 
Protease inhibitor cocktail      Sigma, Steinheim, Germany 
Protease Inhibitor Cocktail Set III, EDTA free (#539134) Calbiochem, MA, USA 
Schiff’s reagent Amber Scientific, Midvale, WA, 
Australia 
Sodium azide (NaN3) (#S2002)    Sigma, Steinheim, Germany 
Sodium chloride (NaCl)     Sigma, Steinheim, Germany 
TiterMax Gold adjuvant     Sigma, Saint Louis, USA 
Toluidine Blue O      Sigma, Steinheim, Germany 
Tris (4855.2)       Carl Roth, Karlsruhe, Germany 
Triton X-100        Sigma, Steinheim, Germany 
Tween-20        Carl Roth, Karlsruhe, Germany 
Tramadol STADA 50mg Tabs STADApharm GmbH, Bad Vilbel, 
Germany  
VECTASHIELD antifade Mounting Medium with DAPI Vector, Burlingame, USA 
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Zydol (Tramadol Hydrochloride Capsules) 50mg capsules Aspen Pharmacare, St Leonards, 
NSW, Australia 
5.1.3. Enzymes 
Collagenase A (#C-0130)  Sigma, St Louis, USA  
DNase I (#DN-25) Sigma, St Louis, USA 
Hyaluronidase, from sheep testes (# H2126)  Sigma, St Louis, USA  
Soybean trypsin inhibitor (# 17075-029)  Gibco, Grand Island, NY, USA 
Trypsin, from porcine pancreas (# T9201)  Sigma, St Louis, USA 
 
5.1.4. Kits 
ApopTag® Peroxidase In Situ Apoptosis Detection Kit Merck, Darmstadt, Germany 
iTaq Universal SYBR Green Supermix (#172-5124) Biorad, München, Germany 
Pierce BCA Protein Assay (#23227) Thermo Scientific, Rockford, IL, USA  
Liquid DAB+substrate chromogen system (#K3468) DAKO, Carpinteria, CA, USA 
Power SYBR green PCR Master Mix (4367659) Applied Biosystems, Warrington, UK 
RNase-Free DNase Set (#79254) Qiagen, Hilden, Germany 
RNeasy Mini kit       Qiagen, Hilden, Germany 
Superscript III first strand Synthesis System for RT-PCR  Invitrogen, Carlsbad, USA 
SYBR Green PCR Kit      Qiagen, Hilden, Germany 
Testosterone kit (Immunotech IM1119) Beckman Coulter, Prague, Czech 
Republic 
Vectastain Elite ABC Kit-standard (#PK6100) Vector Laboratories, Burlingame, 
USA 
 
5.1.5. List of Equipment 
96 well Costar plates (#3361) Corning, NY, USA 
Cell culture CO2 incubator      Binder, Tuttlingen, Germany 
Centrifuge (5424R)       Eppendorf, Hamburg, Germany 
Centrifuge       Sigma, Osterode am harz, Germany 
CFX touchTM Real-time PCR detection system  Biorad, München, Germany 
Cold Plate for Tissue Embedding EG1150C   Leica, Mount Waverly, Australia 
Cryostat CM30509 Leica, Wetzlar, Germany 
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Desktop centrifuge  Biofuge Fresco Heraeus, Hanau, 
Germany 
Electronic balance SPB50      Ohaus, Giessen, Germany 
Electronic balance (mettlerAE240) Mettler Todelo, Greifensee, 
Switzerland 
Electronic balance (Adventurer) OHAUS, Parsippany, NJ USA 
Fast Real-Time PCR system (7900HT) Applied Biosystems, Forest city, 
USA 
Fluorescent Microscope (Olympus IX70) Olympus, Shinjuku, Japan 
Fluorescent microscope Axioplan 2 Imaging   Carl Zeiss, Göttingen, Germany 
Gel Jet Imager 2000 documentation system   Intas, Göttingen, Germany 
Homogenizer (PRO200) Proscientific, Oxford, USA 
MicroAmp Optical 384-well Reaction plate Applied biosystems, Warrington, UK 
MicroAmp Optical Adhesive Film PCR compatible Applied biosystems, Foster city, 
USA 
Microplate ELISA reader (Multiscan RC)  Labsystems, Vantaa, Finland 
Microplate reader       Berthold, Bad Wildbad, Germany 
Microtome RM2255      Leica, Wetzlar, Germany 
Microwave oven       Samsung, Schwalbach, Germany 
Mini centrifuge Galaxy      VWR International 
Mini-rocker shaker MR-1      PEQLAB, Erlangen, Germany 
Mixer Mill MM 300       Retsch, Haan, Germany 
MyiQTM2 Two-Color real-time PCR detection system Bio-Rad, Munich, Germany 
NanoDrop ND 2000       Promega, Mannheim, Germany 
Nanodrop ND-1000 Spectrophotometer ThermoFisher Scientific, Waltham, 
Mass, USA 
Paraffin dispenser embedding module EG1140H Leica, Mount Waverly, Australia 
PCR thermocycler (GeneAmp PCR system 9700) Applied Biosystems, Forest city, 
USA 
Plate Shaker RATEK instruments, Boronia, 
Australia 
PCR thermocycler       Biozyme, Oldendor, Germany 
PCR thermocycler       Peqlab, Erlagen, Germany 
Potter S homogenizer      B. Braun, Melsungen, Germany 
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Power supply units       Consurs, Reiskirchen, Germany 
Roller (SRT1)  Stuart Scientific, Staffordshire, UK 
Stainless steel beads, 5mm (#69989) Qiagen, Hilden, Germany 
SuperFrost Plus microscope slides  R.Langenbrinck, Emmendingen, 
Germany 
Tips and tubes Axygen, Union City, USA 
Tissue Lyser LT (SN23.1001/05705) Qiagen, Hilden, Germany 
Vortex Mixer RATEK instruments, Boronia, 
Australia 
 
5.1.6. PCR reagents 
DNA Ladder (100 bp)      Promega, Mannheim, Germany 
DNase I        Qiagen, Hilden, Germany 
Desoxyribonukleosidtriphosphate (dNTP) 10mM  Promega, Mannheim, Germany 
iTaq Universal SYBR Green Supermix (#172-5124) Biorad, München, Germany 
Moloney Murine Leukemia Virus  
Reverse Transcriptase (M-MLV RT)     Promega, Mannheim, Germany 
Oligo dT 15 Primer      Promega, Mannheim, Germany 
Power SYBR green PCR Master Mix (4367659) Applied Biosystems, Warrington, UK 
QuantiTect SYBR Green PCR Kit     Qiagen, Hilden, Germany 
Recombinant RNasine Ribonuclease inhibitor  Promega, Mannheim, Germany 
Superscript III first strand Synthesis System for RT-PCR  Invitrogen, Carlsbad, USA 
SYBR Green PCR Kit      Qiagen, Hilden, Germany 
Taq polymerase       Promega, Mannheim, Germany 
 
5.2. Buffers and solutions 
1% aqueous acetic acid  
1% glacial acetic acid in distilled water 
 
0.5% acid alcohol  
0.5% concentrated hydrochloric acid in 70% aqueous ethanol 
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Aniline blue staining solution  
2.5% aniline blue  
2.5% glacial acetic acid in distilled water  
 
Biebrich scarlet-acid fuchsin staining solution  
0.9% Biebrich scarlet  
0.1% acid fuchsin  
1% glacial acetic acid in distilled water 
 
Bouin’s fixative  
25% formalin  
75% saturated aqueous picric acid  
5% glacial acetic acid  
 
Celestin Blue R  
5% ferric ammonium sulphate  
0.5% Celestin Blue in distilled water 
Boil on a hot plate, cool rapidly using a magnetic stirrer and add 
14% glycerin  
 
Citrate buffer for antigen retrieval 
1,92 g/l citric acid (10mM) in distilled water, pH 6,0 
 
Munõs Buffer 
25 mM Tris (MW 121.14 g/l)  
0.5 M NaCl (MW 58.44 g/l) 
0.017% Triton X-100 in distilled water, pH 7.6 
 
TAE Buffer 
40 mM Tris-acetate 
1 mM EDTA, pH 8 
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TBST (Tris Buffered Saline with Tween) 
10 x:  24 g/l Tris base (Molecular weight: 121.14 g/l) 
88 g/l NaCl (Molecular weight: 58.4 g/l) 
Distilled water 
pH 7.6  
1 x: 10% of 10x TBST in distilled water,  
pH 7,6 
0,1 % Tween20 
 
Blocking buffer 
10 % normal goat serum in TBST 
 
Toluidine blue staining solution: 
Toluidine blue stock solution:  1% toluidine blue O in 70% Ethanol    
1% sodium chloride:   1 % sodium chloride in distilled water 
pH 2.0 ~2.5 (Solution should be made fresh) 
Toluidine Blue working solution: 10% toluidine blue stock solution in 1% sodium 
chloride 
pH 2.3 (Solution should be made fresh) 
 
5% aqueous phosphotungstic acid  
5% phosphotungstic acid in distilled water 
 
Weigert’s Iron Hematoxylin 
Solution A: 1% of Hematoxylin powder in absolute ethanol  
Solution B: 1.16% ferric chloride  
1% concentrated hydrochloric acid 
Distilled water 
Mix solution A and B in equal parts  
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5.3. Buffers and solutions for cell culture 
1 mg/ml DNAse  
1 mg/ml DNAse in D-PBS (+) 
 
1 mg/ml trypsin 
1 mg/ml Trypsin in DMEM/F12 
0.02 mg/ml DNAse 
 
0.1 mg/ml Soybean trypsin inhibitor (SBTI) 
0.1 mg/ml SBTI in D-PBS (+) 
0.01 mg/ml DNAse 
 
1 mg/ml collagenase 
1 mg/ml collagenase in DMEM/F12 
6 µg/ml DNAse 
 
1 mg/ml hyaluronidase 
1 mg/ml hyaluronidase in DMEM/F12 
6 µg/ml DNase 
 
DMEM/F12 
0.5% L- glutamine (200 mM) 
1% non-essential amino acids [100x] 
1% penicillin / streptomycin (10,000 IU / 10,000 µg/ml)  
Store at 4ºC 
 
DMEM 
1% non-essential amino acids [100x]  
1% penicillin / streptomycin (10,000 IU / 10,000 µg/ml) 
Store at 4ºC 
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Sertoli cell culture medium 
0.1% BSA in DMEM 
Filter sterile 
 
Peritubular cell culture medium 
10% FCS in DMEM 
 
5.4. Primary antibodies 
Anti-smooth muscle actin FITC-conjugated IgG (F3777)  Sigma, Saint Louis, USA 
E4 mouse anti-activin A Oxford Brooks University, 
Oxford, UK 
Mouse monoclonal anti-PCNA (M0879) Dako, Glostrup, Denmark 
Rabbit polyclonal anti-Sox9 (sc-20095) Santa Cruz Biotechnology, 
Dallas, USA 
Rat anti-mouse CD206 (mannose receptor) (ab64693) Abcam, Cambridge, UK 
Rat anti-mouse F4/80 (MCA497G) AbD Serotec, Kidlington, 
UK 
 
5.5. Secondary antibodies 
Streptavidin-AlexaFluor 488 (S32354) Invitrogen (molecular 
probes), Eugene, USA 
F(ab’)2-goat anti-rabbit IgG (H+L) AlexaFluor546 (A11071) Life Technologies, 
Carlsbad, USA 
HRP-labeled polymer anti-rabbit (K4003)   (Dako, Glostrup, Denmark) 
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5.6. Primers 
Table 7: Primers used in quantitative RT-PCR experiments in this study. 
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6. SUMMARY 
Experimental autoimmune epididymo-orchitis (EAEO) is a rodent model of chronic 
testicular inflammation that reproduces the pathology observed in some types of human 
infertility, characterized by elevated levels of pro-inflammatory cytokines, immune cell 
recruitment, germ cell loss and ultimately sub- or infertility. 
Activins A and B are pro-inflammatory, pro-fibrotic cytokines, but also regulate 
spermatogenesis and steroidogenesis under normal conditions. The roles of activin A, B 
and the endogenous activin antagonists, inhibin and follistatin, were examined in EAEO. 
The disease was induced in adult mice by immunization with syngeneic testicular 
homogenate. 
Age-matched untreated mice and controls showed no pathology, with activin A localized 
to Sertoli cells and interstitial macrophages. Immunized mice developed EAEO by 50 
days (induction rate of 100%), and were characterized by a >50% reduction in testis 
weight, complete loss of germ cells, and a marked peritubular fibrotic response. Similar 
changes were also observed in biopsies from human testes with inflammatory infiltrates. 
Moreover, changes were accompanied by increased expression of key inflammatory 
mediators such as tumor necrosis factor, monocyte chemoattractant protein-1 and 
interleukin-10. An increase of the total CD45+ leukocytes, comprising CD3+ T cells, 
CD4+CD8- and CD4+CD25+ T cells, and a novel population of CD4+CD8+ double 
positive T cells was also detected in EAEO testes. Activin A and B protein levels were 
significantly increased in EAEO testes at 50 days, compared with untreated controls but 
not at 80 days, whereas the inhibin subunit mRNA levels (Inha and Inhbb) decreased in 
EAEO testes, becoming significantly lower after 80 days compared with control animals. 
Activin A receptor acvr1b and acvr2b mRNA levels were also significantly decreased in 
EAEO testes. In contrast, testicular follistatin levels were significantly elevated at 50 and 
80 days of EAEO. 
These data suggest that there is a direct association between the onset of EAEO and 
increased activin expression. Therefore, activin may play a role in promoting 
inflammation and fibrosis during EAEO in mouse testis.  
Consequently, the development of EAEO in a mouse model with elevated circulating 
levels of the activin antagonist follistatin (FST), was examined. Follistatin levels were 
increased by a single injection of a non-replicative recombinant adenovirus-associated 
viral vector carrying a gene cassette of the circulating form of follistatin (FST315). 
Controls received an rAAV injection with an empty cassette. EAEO was induced and 
testes were collected 30 and 50 days after the first immunization. Serum follistatin levels 
were increased 5-fold in FST315-vector injected mice compared with the control group 
30 days after vector injection and remained elevated until the end of the experiment. 
The EAEO induction rate was 40% for the FST315-vector injected group compared with 
75% for the control group. Elevated levels of inflammatory mediators and activins, 
recruitment of immune cells, increased fibrosis, disruption of the blood-testis-barrier, 
and increased apoptosis were directly proportional to the observed testicular damage in 
EAEO. 
These data suggest that blocking activin activity alone, by increasing circulating 
follistatin levels before inducing EAEO, was not sufficient to inhibit the development of 
testicular inflammation and fibrosis.  
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7. ZUSAMMENFASSUNG 
Die experimentelle Autoimmun-Epididymo-Orchitis (EAEO) stellt ein Nagermodell für 
chronische Entzündungen des Hodens dar, das besonders in der früheren Phase der  
Erkrankung bestimmte Formen idiopathischer, immunologisch-bedingter Infertilität des 
Mannes gut reproduzieren kann. Schlüsselcharakteristika bei der EAEO und 
entsprechenden Erkrankungen des Mannes sind erhöhte Konzentrationen pro-
inflammatorischer Zytokine, die Akkumulation von Leukocyten im Organ sowie ein 
Verlust von Keimzellen mit nachfolgender Sub- bzw. Infertilität. Activin A und B sind pro-
inflammatorische und pro-fibrotische Zytokine, die zudem eine wichtige Funktion in der 
Regulation der normalen Spermatogenese und Steroidogenese aufweisen. In dieser 
Studie wurde eine mögliche Funktion von Activin A und B sowie der endogenen Activin-
Antagonisten Inhibin und Follistatin in der Pathogenese der EAEO untersucht. Die 
EAEO wurde durch Immunisierung mit syngenem Hodenhomogenat in adulten Mäusen 
ausgelöst.  
Altersgleiche unbehandelte Mäuse sowie Sham-Kontrollmäuse zeigten keine 
pathologischen Veränderungen im Verlauf der Untersuchung, wobei Activin A 
immunhistochemisch in Sertoli-Zellen und interstitiellen Makrophagen gefunden wurde. 
Dagegen entwickelten alle immunisierten Mäuse nach 50 Tagen eine EAEO 
(Induktionsrate 100%) und waren durch eine mehr als 50%ige Reduktion des 
Hodengewichts, einem vollständigen Verlust der Keimzellen und eine deutliche 
fibrotische Reaktion charakterisiert. Ähnliche Veränderungen werden auch in Biopsien 
mit entzündlichen Infiltraten im Hoden beim Mann beobachtet. Darüber hinaus wurde 
die Entwicklung der EAEO durch eine erhöhte Expression entzündlicher Mediatoren wie 
des Tumor-Nnekrose Faktors (TNF), des Monocyte Chemoattractant Protein-1 (MCP-1) 
und von Interleukin-10 (IL-10) begleitet. Zusätzlich wurde eine starke Zunahme der 
gesamten CD45+ Leukozytenpopulation, die aus CD3+ T Zellen, CD4+CD8- und 
CD4+CD25+ T Zellen, sowie einer neuen Population von CD4+CD8+ doppelt positiven 
T Zellen besteht, beobachtet. Im Vergleich zu den Kontrolltieren waren die 
Proteinkonzentrationen von testikulärem Activin A und B Protein bei den EAEO-Tieren 
50 Tage, nicht jedoch 80 Tagen, nach Induktion der EAEO deutlich erhöht. Dagegen 
sanken die testikulären mRNA Level der Inhibin Untereinheiten Inha und Inhb im 
Verlauf der EAEO und waren nach 80 Tagen deutlich niedriger als bei den 
Kontrolltieren. Auch die mRNA Level der Activinrezeptoren acvr1b and acvr2b waren in 
den EAEO Hoden deutlich reduziert, wogegen die testikulären Follistatin 
Konzentrationen in der EAEO-Gruppe sowohl nach 50 als auch nach 80 Tagen im 
Serum deutlich erhöht gemessen worden. Diese Ergebnisse legen nahe, dass es eine 
Verbindung zwischen der Entwicklung einer EAEO und erhöhter Activinexpression gibt 
und Activin die Entwicklung einer Hodenentzündung und –fibrose während der EAEO 
fördern könnte.  
 
Die Rolle von Activin in der EAEO sollte anschließend in vivo in einem Mausmodell 
untersucht werden, in dem die Serum Follistatin-Konzentrationen experimentell durch 
i.m. Applikation eines nicht-replizierenden, rekombinanten adenoassoziierten Virus 
Vektors (rAAV), der eine Expressionskassette für die zirkulierende Follistatin Isoform 
(FST315) besitzt, erhöht wird. Kontrolltiere erhielten einen Vektor mit leerer 
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Expressionskassette. Nach Induktion einer EAEO in diesen Tieren wurden die Hoden 
30 und 50 Tage nach der ersten Immunisierung entnommen. Nach 30 Tagen waren die 
Serum Follistatin Konzentrationen bei den FST315 überexprimierenden Mäusen 5-fach 
erhöht und blieben es auch bis zum Ende des Experimentes. Die EAEO Induktionsrate 
betrug 40% für die FST315 überexprimierenden Mäuse verglichen mit 75% in der 
Kontrollgruppe. Erhöhte Konzentrationen an entzündlichen Schlüsselmediatoren, 
Activin A und B, leukocytäre Infiltrate, eine erhöhte Fibrosierung, eine beeinträchtigte 
Blut-Hodenschranke und vermehrte Apoptose von Keimzellen waren direkt proportional 
zu pathologischen Veränderungen in der Hodenmorphologie der EAEO-Gruppe. 
 
Diese Ergebnisse deuten darauf hin, dass eine alleinige Blockierung der Aktivinaktivität 
durch Erhöhung der Konzentration an zirkulierendem Follistatin vor und während der 
Induktion der EAEO, nicht ausreicht um die Entwicklung einer Hodenentzündung und –
fibrose vollständig zu verhindern. 
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